

10580306

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	3	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	4	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	5	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	6	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	7	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS	8	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	9	NOV 26	MARPAT enhanced with FSORT command
NEWS	10	NOV 26	MEDLINE year-end processing temporarily halts availability of new fully-indexed citations
NEWS	11	NOV 26	CHEMSAFE now available on STN Easy
NEWS	12	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	13	DEC 01	ChemPort single article sales feature unavailable
NEWS	14	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	15	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	16	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	17	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS EXPRESS	JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

10580306

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:14:56 ON 11 JAN 2009

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 13:15:05 ON 11 JAN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JAN 2009 HIGHEST RN 1093164-92-1

DICTIONARY FILE UPDATES: 9 JAN 2009 HIGHEST RN 1093164-92-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10580306.str

10580306



```
chain nodes :
10 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
11
chain bonds :
2-11 4-10 9-12 10-13 10-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
2-11 4-10 5-7 6-9 7-8 8-9 10-13 10-14
exact bonds :
9-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
```

G1:H,CH3


```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:CLASS
```

L1 STRUCTURE UPLOADED

=> d

10580306

L1 HAS NO ANSWERS
L1 STR



G1 H, Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:15:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 85 TO ITERATE

100.0% PROCESSED 85 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1147 TO 2253
PROJECTED ANSWERS: 849 TO 1831

L2 50 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 13:15:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1716 TO ITERATE

100.0% PROCESSED 1716 ITERATIONS 1352 ANSWERS
SEARCH TIME: 00.00.01

L3 1352 SEA SSS FUL L1

=> fil capl

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	185.88	186.10

FILE 'CAPLUS' ENTERED AT 13:15:32 ON 11 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

10580306

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jan 2009 VOL 150 ISS 3
FILE LAST UPDATED: 9 Jan 2009 (20090109/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 13

L4 11 L3


=> d 14 ibib abs hitstr 1-11

10580306

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1338353 CAPLUS
DOCUMENT NUMBER: 149:525391
TITLE: Combinations comprising pregabalin
INVENTOR(S): Gunn, Kevin Paul
PATENT ASSIGNEE(S): Pfizer Limited, UK
SOURCE: PCT Int. Appl., 45pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008132589	A1	20081106	WO 2008-IB1027	20080418
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080293746	A1	20081127	US 2008-112681	20080430
PRIORITY APPLN. INFO.:			US 2007-915174P	P 20070501
AB	The invention relates to a combination of pregabalin and 1-(2-ethoxyethyl)-5-[ethyl(methyl)arnino]-N-mesyl-7-[(4-methyl-2-pyridyl)amino]-1H-pyrazolo[4,3-d]pyrimidine-3-carboxamide, to pharmaceutical compns. containing the combination, and to the use of the combination in the treatment of pain. This combination fully reversed static allodynia, indicating an increased effect if compared to pregabalin alone.			
IT	853003-48-2 1075087-53-4 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combinations comprising pregabalin)			
RN	853003-48-2 CAPLUS			
CN	1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)			

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 1075087-53-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 853003-48-2

CMF C20 H28 N8 O4 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


CM 2

CRN 148553-50-8

CMF C8 H17 N O2

Absolute stereochemistry. Rotation (+).

10580306



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:538718 CAPLUS

DOCUMENT NUMBER: 146:521809

TITLE: Preparation of
 1-[1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxylic acid as a phosphodiesterase 5 (PDE5) inhibitor.

INVENTOR(S): Tollefson, Michael Brent

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 89pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007054778	A1	20070518	WO 2006-IB3132	20061031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
NL 2000291	A1	20070511	NL 2006-2000291	20061027
AU 2006313486	A1	20070518	AU 2006-313486	20061031
CA 2629339	A1	20070518	CA 2006-2629339	20061031
EP 1948661	A1	20080730	EP 2006-809195	20061031
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
IN 2008DN03942	A	20080815	IN 2008-DN3942	20080508
CN 101305007	A	20081112	CN 2006-80041698	20080508
MX 200806083	A	20080522	MX 2008-6083	20080509
KR 2008063830	A	20080707	KR 2008-711230	20080509
NO 2008002593	A	20080722	NO 2008-2593	20080610
PRIORITY APPLN. INFO.:			US 2005-735320P	P 20051110
			WO 2006-IB3132	W 20061031

AB 1-[1-(2-Ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxylic acid (I) was prepared I (6-step preparation from 3-ethyl-4-nitropyrazole-5-carboxamide, 2-ethoxyethanol, carbonyldiimidazole, 2-amino-4-picoline, and isonipecotic acid given) inhibited human platelet PDE5 with IC50 = 0.047 nM.

IT 936449-28-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of a pyrazolopyrimidinylpiperidinecarboxylic acid as a PDE5 inhibitor)

10580306

RN 936449-28-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 792966-67-7 792966-68-8 792966-69-9
792966-70-2 792966-73-5 792966-74-6
792966-75-7 792966-77-9 792966-78-0
792966-79-1 792966-80-4 792966-81-5
792966-82-6 792966-83-7 792966-84-8
792966-85-9 792966-90-6 792966-92-8
792966-94-0 792967-01-2 792967-02-3
792967-03-4 792967-04-5 792967-05-6
792967-06-7 792967-62-5 792967-63-6
792967-73-8 792967-76-1 792967-77-2
792967-79-4 792967-80-7 792967-84-1
792967-86-3 792967-87-4 792967-88-5
792967-89-6 792967-90-9 792967-91-0
792967-92-1 792967-94-3 792967-95-4
792967-96-5 792967-99-8 792968-04-8
792968-05-9 792968-06-0 792968-09-3
792968-10-6 792968-19-5 792968-20-8
792968-21-9 792968-22-0 792968-23-1
792968-24-2 792968-25-3 792968-26-4
792968-29-7 792968-30-0 792968-31-1
792968-32-2 792968-33-3 792968-34-4
792968-35-5 792968-36-6 792968-37-7
792968-38-8 792968-39-9 792968-40-2
792968-41-3 792968-42-4 792968-43-5
792968-44-6 792968-45-7 792968-46-8
792968-47-9 792968-48-0 792968-49-1
792968-51-5 792968-52-6 792968-53-7
792968-54-8 792968-55-9 792968-56-0
792968-57-1 792968-58-2 792968-60-6
792968-61-7 792968-62-8 792968-63-9
792968-64-0 792968-66-2 792968-76-4
792968-78-6 792968-79-7 792968-82-2
792968-85-5 792968-88-8 792968-89-9
792968-90-2 792968-91-3 792968-92-4
792968-93-5 792968-94-6 792968-95-7
792968-96-8 792968-97-9 792968-98-0
792968-99-1 792969-00-7 792969-02-9


10580306

792969-04-1 792969-05-2 792969-06-3
792969-08-5 792969-09-6 792969-10-9
792969-11-0 792969-12-1 792969-13-2
792969-14-3 792969-15-4 792969-16-5
792969-17-6 792969-18-7 792969-19-8
792969-20-1 792969-23-4 792969-24-5
792969-25-6 792969-26-7 792969-29-0
792969-31-4 792969-32-5 792969-33-6
792969-34-7 792969-35-8 792969-38-1
792969-39-2 792969-40-5 792969-42-7
792969-43-8 792969-44-9 792969-46-1
792969-47-2 792969-48-3 792969-49-4
792969-50-7 792969-53-0 792969-54-1
792969-56-3 792969-57-4 792969-59-6
792969-60-9 792969-61-0 792970-85-5
792970-88-8 794511-53-8 936647-49-3
936647-50-6 936647-53-9 936647-56-2
936647-65-3 936647-67-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(preparation of substituted pyrazolopyrimidines as PDE5 inhibitors)

RN 792966-67-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-1-(2-methoxyethyl)-N5-methyl-N7-(4-methyl-2-pyridinyl)- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-68-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-4-
pyrimidinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-69-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3-amino-1-azetidiny)-1-(2-ethoxyethyl)-3-ethyl-N-4-pyrimidinyl- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-70-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-1-(2-
propoxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-73-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(5-methyl-2-pyridinyl)-1-(2-propoxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-74-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-methoxyethyl)-3-(1-methylethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(5-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-75-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-1-(1-methylethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(5-methyl-2-
pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-77-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-78-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-79-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-(1-methylethyl)-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-80-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3S)-3-(1-methylethyl)-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-81-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-82-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-83-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-(1-methylethyl)-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-84-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3S)-3-(1-methylethyl)-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-85-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-ethyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-90-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-1-(1-methylethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-92-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-4-
pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-94-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 792967-01-2 CAPLUS

CN 4-Piperidinol, 1-[1-methyl-7-[(5-methyl-2-pyridinyl)amino]-3-propyl-1H-
pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-02-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-N-(5-methyl-2-pyridinyl)-5-(1-piperidinyl)-3-propyl- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-03-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-3-azetidiny1-1-methyl-N7-(5-methyl-2-pyridinyl)-3-propyl- (CA INDEX
NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-04-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-3-azetidinyln-5,1-dimethyl-N7-(5-methyl-2-pyridinyl)-3-propyl- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-05-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[(3S)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-3-propyl-
(CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-06-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-3-propyl-
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-62-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-[(4-methoxyphenyl)methyl]-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-63-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(2-methoxyethyl)-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-73-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10580306


RN 792967-76-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(4-methyl-1-piperazinyl)-3-propyl-N-4-pyrimidinyl- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-77-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[(3S)-3-methyl-1-piperazinyl]-3-propyl-N-4-pyrimidinyl- (CA
INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-79-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(6-methoxy-4-pyrimidinyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-80-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(6-methoxy-4-pyrimidinyl)-N5,1-dimethyl-3-propyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-84-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(1-piperazinyl)-3-propyl-N-3-pyridazinyl- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-86-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-1H-imidazol-2-yl-N5,1-dimethyl-3-propyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-87-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[(3R)-3-methyl-1-piperazinyl]-3-propyl-N-4-pyrimidinyl- (CA
INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-88-5 CAPLUS

CN Ethanol, 2-[[1-(3-methoxypropyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-
1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-89-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,1-bis(2-methoxyethyl)-3-methyl-N7-(4-methyl-2-pyridinyl)- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-90-9 CAPLUS

CN 4-Piperidinol, 1-[3-ethyl-1-(2-methoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-91-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-methoxyethyl)-5-[(3S)-3-methoxy-1-pyrrolidinyl]-3-methyl-N-(4-methyl-
2-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-92-1 CAPLUS

CN Ethanol, 2-[[1-(3-methoxypropyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-
1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-94-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-1-(2-methoxyethyl)-N7-(4-methyl-2-pyridinyl)-N5-[(2S)-2-
pyrrolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-95-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(3-methoxypropyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-96-5 CAPLUS

CN 3-Pyrrrolidinol, 1-[1-(3-methoxypropyl)-3-methyl-7-[(4-methyl-2-
pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (3R)- (CA INDEX
NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-99-8 CAPLUS

CN 1-Propanol, 3-[[3-ethyl-1-(2-methoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-04-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-1-(2-methoxyethyl)-N-(5-methyl-2-pyridinyl)-5-(4-morpholinyl)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-05-9 CAPLUS

CN Ethanol, 2-[[3-ethyl-1-(2-methoxyethyl)-7-(2-pyridinylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-06-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N7-(5-fluoro-2-pyridinyl)-N5,1-bis(2-methoxyethyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-09-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(4-methyl-1-piperazinyl)-N-(5-methyl-2-pyridinyl)-3-propyl-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-10-6 CAPLUS

CN 1-Propanol, 2-[[7-[(4,6-dimethyl-2-pyridinyl)amino]-1-(3-methoxypropyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2S)-
(CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-19-5 CAPLUS

CN	1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(5-ethyl-2-pyridinyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (NAME)	(CA INDEX
----	--	-----------




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-20-8 CAPLUS


CN	1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-cyclohexyl-1-methyl-5-(1-piperazinyl)-3-propyl-	(CA INDEX NAME)
----	---	-----------------

10580306



RN 792968-21-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4,6-dimethyl-2-pyridinyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-22-0 CAPLUS


CN Cyclohexanol, 4-[[1-methyl-5-(1-piperazinyl)-3-propyl-1H-pyrazolo[4,3-
d]pyrimidin-7-yl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.

10580306




RN 792968-23-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-methoxycyclohexyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (CA INDEX
NAME)



RN 792968-24-2 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-6-[[1-methyl-5-(1-piperazinyl)-3-propyl-1H-
pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-25-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-cyclopentyl-1-methyl-5-(1-piperazinyl)-3-propyl- (CA INDEX NAME)



RN 792968-26-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,N7,1-trimethyl-N7-(1-methyl-4-piperidinyl)-3-propyl- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-31-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-32-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-33-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-34-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-35-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-36-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-37-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-38-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-39-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-40-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-41-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-42-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-43-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-44-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-45-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-46-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-47-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-1-(2-methoxyethyl)-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-48-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-1-(2-methoxyethyl)-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-49-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-1-(2-methoxyethyl)-N7-(4-methyl-2-pyridinyl)-N5-[2-(1H-pyrazol-1-yl)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-51-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-methoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3R)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-52-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3R)-1-
methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-53-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,3-dimethyl-N5-[(3R)-1-methyl-3-pyrrolidinyl]-N7-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-54-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-N5-[(3R)-1-
methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-55-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(5-methyl-2-pyridinyl)-N5-[(3R)-1-
methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-56-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-[(3R)-1-methyl-3-pyrrolidiny]-N7-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-57-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3S)-1-
methyl-3-pyrrolidiny]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-58-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-N5-[(3S)-1-
methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-60-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-61-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-methoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-62-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[(tetrahydro-2-
furanyl)methyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-63-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-(2-pyridinylmethyl)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-64-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[(tetrahydro-2H-
pyran-2-yl)methyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-66-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-(2,2,2-
trifluoroethyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-76-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-methoxyethyl)-3-(1-methylethyl)-N-(5-methyl-2-pyridinyl)-5-(1-
piperazinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-78-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-79-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-82-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-N5,N5-dimethyl-N7-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-85-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-(ethoxymethyl)-N5,N5-dimethyl-N7-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-88-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,3-dimethyl-N5-[(3S)-1-methyl-3-pyrrolidinyl]-N7-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-89-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(5-methyl-2-pyridinyl)-N5-[(3S)-1-
methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-90-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-[(3S)-1-methyl-3-pyrrolidinyl]-N7-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-91-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(6-methoxy-3-pyridinyl)-3-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 792968-92-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(5-methoxy-2-pyridinyl)-3-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-93-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(6-methoxy-2-pyridinyl)-3-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-94-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-
pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-95-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-96-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(5,6-dimethyl-3-pyridinyl)-1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 792968-97-9 CAPLUS

CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 792968-98-0 CAPLUS


CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-5-[(2-methoxyethyl)methylamino]-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-methyl- (CA INDEX NAME)

10580306



RN 792968-99-1 CAPLUS


CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-5-(ethylmethylamino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-methyl- (CA INDEX NAME)



RN 792969-00-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[3-(methylamino)-1-azetidiny]-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-02-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[3-(dimethylamino)-1-azetidiny]-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-
2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-04-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-
2-yl]-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-05-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-(2-methoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-06-3 CAPLUS

CN Ethanol, 2-[[1-(2-ethoxyethyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-
pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-08-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-
2-yl]-N-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-09-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-10-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-ethyl-3-(methoxymethyl)-N5-methyl-N7-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-11-0 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[1-(2-ethoxyethyl)-3-(methoxymethyl)-7-[(4-methyl-
2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (2S)- (CA INDEX
NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-12-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-N5-methyl-N5-(1-methyl-4-piperidinyl)-
N7-(4-methyl-2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-13-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[3-(dimethylamino)-1-azetidiny]-1-(2-ethoxyethyl)-3-(methoxymethyl)-N-
(4-methyl-2-pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-14-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-N5,3-dimethyl-N7-4-
pyrimidinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-15-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-ethyl-N5,3-dimethyl-N7-4-pyrimidinyl- (CA INDEX
NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-16-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-ethyl-N5,3-dimethyl-N7-(2-methyl-4-pyrimidinyl)- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-17-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-(2-methoxyethyl)-N5,3-dimethyl-N7-(2-methyl-4-
pyrimidinyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-18-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(2-methyl-4-
pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-19-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-
pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-20-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-23-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-ethyl-3-(methoxymethyl)-N5-methyl-N7-4-pyrimidinyl-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-24-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-(2-methoxyethyl)-3-(methoxymethyl)-N5-methyl-N7-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-25-6 CAPLUS

CN Ethanol, 2-[[1-(2-ethoxyethyl)-3-(methoxymethyl)-7-[(4-methyl-2-
pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]- (CA INDEX
NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-26-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-(4-pyrimidinylamino)- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-29-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-methyl-N-(4-methyl-2-
pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-31-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-N-(5,6-dimethyl-3-pyridinyl)-1-
(2-ethoxyethyl)-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 792969-32-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-N-(4,6-dimethyl-2-pyridinyl)-1-
(2-ethoxyethyl)-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-33-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(6-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-34-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-35-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(2,5-diazabicyclo[2.2.2]oct-2-yl)-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-
2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-38-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-39-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-40-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-1-(2-ethoxyethyl)-3-(methoxymethyl)-N-
(4-methyl-2-pyridinyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-42-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-43-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3S)-1-methyl-3-pyrrolidinyl]-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-44-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(2-methyl-4-pyrimidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-46-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyridazinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 792969-47-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-48-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(2-methyl-4-pyrimidinyl)-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-49-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(6-methyl-4-pyrimidinyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-50-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-53-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-54-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-56-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-57-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-3-(methoxymethyl)-N-(4-methyl-2-
pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-59-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-60-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-methyl-7-[(6-methyl-4-pyrimidinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-61-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-ethyl-7-[(6-methyl-4-pyrimidinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-85-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-1-(2-propoxyethyl)-N-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-88-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-ethyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 794511-53-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)-3-propyl- (CA INDEX
NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 936647-49-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-1-(2-methoxyethyl)-N7-(3-methyl-1H-pyrazol-5-yl)-N5-[2-(1H-pyrazol-1-yl)ethyl]- (CA INDEX NAME)



RN 936647-50-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(3-methoxypropyl)-3-methyl-N-(3-methyl-1H-pyrazol-5-yl)-5-(1-piperazinyl)- (CA INDEX NAME)


10580306



RN 936647-53-9 CAPLUS

CN 1-Propanol, 2-[[3-ethyl-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 936647-56-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-1-(2-methoxyethyl)-N-(3-methyl-1H-pyrazol-5-yl)-5-(1-piperazinyl)-
(CA INDEX NAME)


10580306



RN 936647-65-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(methoxymethyl)-N-(3-methylphenyl)-5-[(3R)-3-methyl-1-piperazinyl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 936647-67-5 CAPLUS

CN 2(1H)-Pyridinone, 5-[[5-(ethylmethylamino)-3-(methoxymethyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-methyl- (CA INDEX NAME)

10580306



REFERENCE COUNT:

5


THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:251842 CAPLUS
 DOCUMENT NUMBER: 146:316925
 TITLE: Preparation of pyrazolopyrimidines for treatment of inflammatory diseases
 INVENTOR(S): Kono, Norimasa; Koganemaru, Yohei; Hamaguchi, Wataru; Masuda, Naoyuki; Kato, Koji; Yokoyama, Kazuhiro; Miyazaki, Takahiro
 PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 38pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2007055940	A	20070308	JP 2005-243425	20050824
PRIORITY APPLN. INFO.:			JP 2005-243425	20050824
OTHER SOURCE(S):	MARPAT	146:316925		

GI




AB Title compds. I [R1, R2 = C1-6 (halo)alkyl, H; A = bond, CH2; R3 = (un)substituted ph; R4 = (un)substituted cyclic amino] or their pharmacol. acceptable salts are prepared Thus, N-[(4-chloro-2-fluorophenyl)methyl]-3-methyl-5-piperazin-1-yl-1H-pyrazolo[4,3-d]pyrimidine-7-amine was amidated with (2R)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid, then the corresponding amide was deprotected by HCl to give I.2HCl [R1 = H, R2 = Me, A = CH2, R3 = 4-chloro-2-fluorophenyl, R4 = 4-[(2R)-piperidin-2-ylcarbonyl]piperazin-1-yl], which inhibited binding of [35S]GTPγS to human CCR4 with IC50 value of ≤100 nM.

IT 928765-98-4P 928766-07-8P 928766-30-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyrimidines as chemokine receptor CCR4 antagonists and anti-inflammatory agents)

RN 928765-98-4 CAPLUS

CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2)
 (CA INDEX NAME)


10580306



●2 HCl

RN 928766-07-8 CAPLUS
CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2), (3S)- (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 928766-30-7 CAPLUS
CN Ethanone, 1-[4-[7-[(4-chloro-2-fluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-1-piperazinyl]-2-[(2S)-2-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.

10580306




●2 HCl

IT 928767-43-5P 928767-44-6P 928767-65-1P
928767-66-2P 928767-67-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of pyrazolopyrimidines as chemokine receptor CCR4 antagonists
and anti-inflammatory agents)
RN 928767-43-5 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-chloro-2-fluorophenyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (CA
INDEX NAME)




RN 928767-44-6 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-chloro-2-fluorophenyl)-1-ethyl-3-methyl-5-(1-piperazinyl)- (CA INDEX
NAME)

10580306



RN 928767-65-1 CAPLUS


CN 4-Piperidinol, 1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




RN 928767-66-2 CAPLUS

CN Carbamic acid, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

10580306



RN 928767-67-3 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
 N-(4-chloro-2-fluorophenyl)-1-ethyl-3-methyl-5-[4-(methyamino)-1-
 piperidinyl]- (CA INDEX NAME)



IT 928765-99-5P 928766-00-1P 928766-01-2P
 928766-02-3P 928766-03-4P 928766-06-7P
 928766-08-9P 928766-09-0P 928766-10-3P
 928766-11-4P 928766-12-5P 928766-13-6P
 928766-14-7P 928766-15-8P 928766-16-9P
 928766-18-1P 928766-19-2P 928766-20-5P
 928766-21-6P 928766-22-7P 928766-25-0P
 928766-26-1P 928766-29-4P 928766-32-9P
 928766-33-0P 928766-35-2P 928766-36-3P
 928766-37-4P 928766-38-5P 928766-39-6P
 928766-40-9P 928766-41-0P 928766-42-1P
 928766-43-2P 928766-44-3P 928766-45-4P
 928766-46-5P 928766-47-6P 928766-48-7P
 928766-49-8P 928766-53-4P 928766-54-5P


928766-55-6P 928766-56-7P 928766-57-8P
 928766-58-9P 928766-59-0P 928766-60-3P
 928766-61-4P 928766-62-5P 928766-63-6P
 928766-64-7P 928766-65-8P 928766-66-9P
 928766-67-0P 928766-68-1P 928766-69-2P
 928766-70-5P 928766-71-6P 928766-72-7P
 928766-74-9P 928766-75-0P 928766-76-1P
 928766-77-2P 928766-78-3P 928766-79-4P
 928766-80-7P 928766-81-8P 928766-82-9P
 928766-83-0P 928766-84-1P 928766-85-2P
 928766-86-3P 928766-87-4P 928766-88-5P
 928766-89-6P 928766-90-9P 928766-91-0P
 928766-92-1P 928766-93-2P 928766-94-3P
 928766-95-4P 928766-96-5P 928766-97-6P
 928766-98-7P 928766-99-8P 928767-00-4P
 928767-02-6P 928767-03-7P 928767-04-8P
 928767-05-9P 928767-06-0P 928767-07-1P
 928767-09-3P 928767-11-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as chemokine receptor CCR4 antagonists and anti-inflammatory agents)

RN 928765-99-5 CAPLUS

CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1,3-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 928766-00-1 CAPLUS

CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-3-ethyl-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2), (3S)- (CA INDEX NAME)


Absolute stereochemistry.

10580306



●2 HCl


RN 928766-01-2 CAPLUS
CN [1,4'-Bipiperidine]-3-methanol, 1'-[1-methyl-3-propyl-7-[(2,4,5-trifluorophenyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 928766-02-3 CAPLUS
CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2,6-difluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2) (CA INDEX NAME)

10580306



● 2 HCl


RN 928766-03-4 CAPLUS
CN [1,4'-Bipiperidine]-3-carboxamide,
1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-
d]pyrimidin-5-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 928766-06-7 CAPLUS
CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-
ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2)
(CA INDEX NAME)


10580306



●2 HCl

RN 928766-08-9 CAPLUS
CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl


RN 928766-09-0 CAPLUS
CN [1,4'-Bipiperidine]-3-carboxamide, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2) (CA INDEX NAME)

10580306



● 2 HCl


RN 928766-10-3 CAPLUS
CN [1,4'-Bipiperidine]-3-carboxamide,
1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-
d]pyrimidin-5-yl]-N-methyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 928766-11-4 CAPLUS
CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1,3-
diethyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2) (CA INDEX
NAME)

10580306




● 2 HCl

RN 928766-12-5 CAPLUS

CN [1,4'-Bipiperidine]-3-methanol, 1'-[3-butyl-7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2), (3S)- (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 928766-13-6 CAPLUS

CN [1,4'-Bipiperidine]-3-carboxamide,
1'-[3-butyl-7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-1H-pyrazolo[4,3-
d]pyrimidin-5-yl]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)


10580306



● HCl

RN 928766-14-7 CAPLUS
CN [1,4'-Bipiperidine]-3-carboxamide,
1'-[3-butyl-7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-1H-pyrazolo[4,3-
d]pyrimidin-5-yl]-, hydrochloride (1:1), (3S)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 928766-15-8 CAPLUS
CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-3-
methyl-1-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2)
(CA INDEX NAME)

10580306



●2 HCl


RN 928766-16-9 CAPLUS
CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 928766-18-1 CAPLUS
CN [2,4'-Bipiperidine]-1-ethanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2) (CA INDEX NAME)

10580306



● 2 HCl


RN 928766-19-2 CAPLUS
CN [2,4'-Bipiperidine]-1-propanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2)
(CA INDEX NAME)



● 2 HCl

RN 928766-20-5 CAPLUS
CN [2,4'-Bipiperidine]-1-propanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1,3-diethyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2) (CA INDEX NAME)


10580306



● 2 HCl

RN 928766-21-6 CAPLUS

CN [2,4'-Bipiperidine]-1-propanol, 1'-[3-butyl-7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 928766-22-7 CAPLUS

CN [2,4'-Bipiperidine]-1-propanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:2) (CA INDEX NAME)


10580306



● 2 HCl

RN	928766-25-0	CAPLUS
CN	Methanone, [4-[7-[(4-chloro-2-fluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-1-piperazinyl](2R)-2-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)	

Absolute stereochemistry.




● 2 HCl

RN	928766-26-1	CAPLUS
CN	Methanone, [4-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-1-piperazinyl] (2R)-2-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)	

Absolute stereochemistry.

10580306




● 2 HCl

RN 928766-29-4 CAPLUS

CN Ethanone, 1-[4-[7-[(4-chloro-2-fluorophenyl)amino]-1,3-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-1-piperazinyl]-2-[(2S)-2-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 928766-32-9 CAPLUS

CN Ethanone, 1-[4-[7-[(4-chloro-2-fluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-1-piperazinyl]-2-[(2S)-1-methyl-2-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)

10580306

Absolute stereochemistry.




● 2 HCl

RN 928766-33-0 CAPLUS

CN Ethanone, 1-[4-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-1-piperazinyl]-2-[(2S)-2-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 928766-35-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N,1-dimethyl-, hydrochloride (1:2), (2S)- (CA INDEX NAME)

10580306

Absolute stereochemistry.




●2 HCl

RN 928766-36-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N,1-dimethyl-, hydrochloride (1:2), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl


RN 928766-37-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl-1-

10580306

methyl-, hydrochloride (1:2), (2S)- (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 928766-38-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl-1-methyl-, hydrochloride (1:2), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl


RN 928766-39-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl-1-methyl-, hydrochloride (1:2), (2R)- (CA INDEX NAME)

10580306

3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyll]-N,1-dimethyl-,
hydrochloride (1:2), (2S)- (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 928766-40-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N,1-dimethyl-,
hydrochloride (1:2), (2R)- (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 928766-41-0 CAPLUS

10580306


CN 1-Propanol, 3-[[1-[7-[(4-chloro-2-fluorophenyl)amino]-1,3-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]cyclobutylamino]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 928766-42-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(4-chloro-2-fluorophenyl)-5-[4-(cyclobutylamino)-1-piperidinyl]-1-methyl-3-propyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 928766-43-2 CAPLUS


CN 1-Propanol, 3-[[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]cyclobutylamino]-, hydrochloride (1:2) (CA INDEX NAME)

10580306



● 2 HCl


RN 928766-44-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-chloro-2-fluorophenyl)-5-[4-(cyclobutylamino)-1-piperidinyl]-1-ethyl-
3-methyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 928766-45-4 CAPLUS
CN 1-Propanol, 3-[[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-
pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]cyclobutylamino]-,
hydrochloride (1:2) (CA INDEX NAME)

10580306



● 2 HCl


RN 928766-46-5 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-chloro-2-fluorophenyl)-5-[4-(cyclobutylamino)-1-piperidinyl]-1,3-
diethyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 928766-47-6 CAPLUS
CN 1-Propanol, 3-[[[1-[7-[(4-chloro-2-fluorophenyl)amino]-1,3-diethyl-1H-
pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]cyclobutylamino]-,
hydrochloride (1:2) (CA INDEX NAME)

10580306



● 2 HCl


RN 928766-48-7 CAPLUS
CN 1-Propanol, 3-[[1-[3-butyl-7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]cyclobutylamino]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 928766-49-8 CAPLUS
CN 1-Propanol, 3-[[1-[7-[(4-chloro-2-fluorophenyl)amino]-3-methyl-1-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]cyclobutylamino]-, hydrochloride (1:2) (CA INDEX NAME)

10580306



● 2 HCl


RN 928766-53-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-chloro-2-fluorophenyl)-5-[4-(cyclopentylamino)-1-piperidinyl]-1-ethyl-
3-methyl- (CA INDEX NAME)



RN 928766-54-5 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-chloro-2-fluorophenyl)-5-[4-(cyclohexylamino)-1-piperidinyl]-1-ethyl-
3-methyl- (CA INDEX NAME)


CC1=NN(C2=CC=CC=C2C(=C1)N3C=CC(=C3)N4C(=CC=CC=C4)N5CCCCC5)C6=CC=C(C=C6)FCC1=NN(C)C2=C1N=CN=C2N(C3CCCCC3)N(C4CCCCC4)C5=CC=C(C=C5)N(F)C6=CC=CC=C6Cl

10580306



RN 928766-57-8 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 928766-58-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(4-chloro-2-fluorophenyl)-5-[4-(cycloheptylamino)-1-piperidinyl]-1-ethyl-3-methyl- (CA INDEX NAME)

10580306




RN 928766-59-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-chloro-2-fluorophenyl)-1-ethyl-3-methyl-5-[4-(1-pyrrolidinyl)-1-
piperidinyl]- (CA INDEX NAME)




RN 928766-60-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[1,4'-bipiperidin]-1'-yl-N-(4-chloro-2-fluorophenyl)-1-ethyl-3-methyl-
(CA INDEX NAME)

10580306



RN 928766-61-4 CAPLUS


CN [1,4'-Bipiperidin]-3-ol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)



RN 928766-62-5 CAPLUS


CN [1,4'-Bipiperidin]-4-ol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)

10580306



RN 928766-63-6 CAPLUS


CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)



RN 928766-64-7 CAPLUS


CN [1,4'-Bipiperidine]-4-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)

10580306



RN 928766-65-8 CAPLUS


CN [1,4'-Bipiperidine]-3-ethanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)



RN 928766-66-9 CAPLUS

CN [1,4'-Bipiperidine]-4-ethanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



RN 928766-67-0 CAPLUS

CN 2-Pyrrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N,1-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 928766-68-1 CAPLUS


CN 3-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N,1-dimethyl- (CA INDEX NAME)

10580306



RN 928766-69-2 CAPLUS


CN 4-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidiny]-N,1-dimethyl- (CA INDEX NAME)



RN 928766-70-5 CAPLUS

CN 1-Piperidinepropanamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidiny]-N-methyl- (CA INDEX NAME)


10580306



RN 928766-71-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidiny]-N-methyl-, (2S)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 928766-72-7 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidiny]-N-methyl-, (2R)-
(CA INDEX NAME)

Absolute stereochemistry.

10580306




RN 928766-74-9 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 928766-75-0 CAPLUS
CN 2-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 928766-76-1 CAPLUS

CN 2-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 928766-77-2 CAPLUS


CN 4-Piperidineacetamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)

10580306



RN 928766-78-3 CAPLUS


CN 2-Morpholinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 928766-79-4 CAPLUS

CN 4-Piperidinepropanamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


10580306



RN 928766-80-7 CAPLUS

CN 2-Pyrrolidineacetamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 928766-81-8 CAPLUS


CN 3-Piperidineacetamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)

10580306



RN 928766-82-9 CAPLUS


CN 2-Piperidinepropanamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 928766-83-0 CAPLUS

CN 3-Pyrrolidineacetamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


10580306



RN 928766-84-1 CAPLUS

CN 2-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-4,4-difluoro-N-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 928766-85-2 CAPLUS

CN 2-Piperidineacetamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.

10580306



RN 928766-86-3 CAPLUS


CN 2-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 928766-87-4 CAPLUS

CN 3-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


10580306



RN 928766-88-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl-1-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 928766-89-6 CAPLUS

CN 3-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl-1-methyl-, (CA INDEX NAME)

10580306




RN 928766-90-9 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl-1-methyl- (CA INDEX NAME)



RN 928766-91-0 CAPLUS
CN 1-Piperidinepropanamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)


10580306



RN 928766-92-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidiny]-N-ethyl-, (2S)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 928766-93-2 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidiny]-N-ethyl-, (2R)-
(CA INDEX NAME)

Absolute stereochemistry.

10580306




RN 928766-94-3 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)



RN 928766-95-4 CAPLUS
CN 2-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 928766-96-5 CAPLUS

CN 2-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 928766-97-6 CAPLUS


CN 4-Piperidineacetamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)

10580306



RN 928766-98-7 CAPLUS


CN 2-Morpholinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)



RN 928766-99-8 CAPLUS

CN 4-Piperidinepropanamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)


10580306



RN 928767-00-4 CAPLUS

CN 2-Pyrrolidineacetamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl-, (2S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 928767-02-6 CAPLUS


CN 3-Piperidineacetamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)

10580306



RN 928767-03-7 CAPLUS


CN 2-Piperidinepropanamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)



RN 928767-04-8 CAPLUS

CN 3-Pyrrolidineacetamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)


10580306



RN 928767-05-9 CAPLUS

CN 2-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl-4,4-difluoro-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 928767-06-0 CAPLUS

CN 2-Piperidineacetamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.

10580306



RN 928767-07-1 CAPLUS


CN 2-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)



RN 928767-09-3 CAPLUS


CN 3-Piperidinecarboxamide, N-[1-[7-[(4-chloro-2-fluorophenyl)amino]-1-ethyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)

10580306



RN 928767-11-7 CAPLUS

CN [1,4'-Bipiperidine]-3-methanol, 1'-[7-[(4-chloro-2-fluorophenyl)amino]-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)



10580306

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1202023 CAPLUS

DOCUMENT NUMBER: 145:505469

TITLE: Anhydrous crystalline forms of
N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide as PDE-5 inhibitors

INVENTOR(S): Entwistle, David Andrew; Marshall, Peter Wallance;
Taylor, Stefan Colin John

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 72pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2006120552	A2	20061116	WO 2006-IB1233	20060503
WO 2006120552	A3	20070118		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006245416	A1	20061116	AU 2006-245416	20060503
CA 2608018	A1	20061116	CA 2006-2608018	20060503
EP 1881985	A2	20080130	EP 2006-744689	20060503
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2006316058	A	20061124	JP 2006-132110	20060511
NO 2007005258	A	20071115	NO 2007-5258	20071012
IN 2007DN08174	A	20071123	IN 2007-DN8174	20071023
MX 200713215	A	20071212	MX 2007-13215	20071023
US 20080194591	A1	20080814	US 2007-913091	20071030
KR 2008004593	A	20080109	KR 2007-726098	20071109
CN 101175758	A	20080507	CN 2006-80016340	20071112
PRIORITY APPLN. INFO.:			US 2005-680445P	P 20050512
			US 2005-681711P	P 20050517
			WO 2006-IB1233	W 20060503

GI



AB The invention comprises anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide (I), pharmaceutical compns. comprising at least one such form, methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and methods for preparing such forms. Example compound I was prepared

by N-alkylation of di-Me 4-nitro-1H-pyrazole-3,5-dicarboxylate with 2-ethoxyethyl bromide; the resulting di-Me 1-(2-ethoxyethyl)-4-nitro-1H-pyrazole-3,5-dicarboxylate, which underwent hydrolysis to give the pyrazole-5-carboxylic acid derivative, which underwent amidation to give the corresponding amide, which underwent reduction to give Me 4-amino-5-carbamoyl-1-(2-ethoxyethyl)-1H-pyrazole-3-carboxylate, which underwent cyclization with N,N'-carbonyldiimidazole to give Me 1-(2-ethoxyethyl)-5,7-dioxo-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate, which which underwent chlorination to give Me 5,7-dichloro-1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate, which underwent substitution with 2-amino-4-methylpyridine; the resulting Me 5-chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate underwent hydrolysis to give the corresponding carboxylic acid, which underwent amidation to give the methanesulfonamide derivative, which underwent substitution with N-methylethylamine to give compound I. Various methods to obtained different crystalline forms of I is also discussed. Compound I was evaluated

for its PDE-5 inhibitory activity.

IT 853003-48-2P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and anhydrous crystalline forms of N-[ethoxyethyl(N-ethyl-N-methylamino)(methylpyridinylamino)pyrazolo[4,3-d]pyrimidinecarbonyl]methanesulfonamide as PDE-5 inhibitors)

RN 853003-48-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methanysulfonyl)- (CA INDEX NAME)

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 853004-52-1P 853006-51-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and anhydrous crystalline forms of

N-[ethoxyethyl(N-ethyl-N-methylamino)(methylpyridinylamino)pyrazolo[4,3-d]pyrimidinecarbonyl]methanesulfonamide as PDE-5 inhibitors)

RN 853004-52-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-,
methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-51-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:412090 CAPLUS

DOCUMENT NUMBER: 144:450729

TITLE: Preparation of novel
5,7-diaminopyrazolo[4,3-d]pyrimidines as PDE5
inhibitors for treating hypertensionINVENTOR(S): Acker, Brad Alan; Hughes, Robert Owen; Jacobsen, Eric
John; Lu, Hwang-Fun; Rogers, Thomas Edward; Tollefson,
Michael Brent; Walker, John Keith

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company LLC, USA

SOURCE: PCT Int. Appl., 244 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006046135	A2	20060504	WO 2005-IB3326	20051017
WO 2006046135	A3	20060817		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2585557	A1	20060504	CA 2005-2585557	20051017
EP 1809632	A2	20070725	EP 2005-800579	20051017
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2008517994	T	20080529	JP 2007-538544	20051017
PRIORITY APPLN. INFO.:			US 2004-622941P	P 20041028
			WO 2005-IB3326	W 20051017
OTHER SOURCE(S):	MARPAT 144:450729			
GI				



AB Title compds. I [R1 = (un)substituted independently Ph, naphthyl, heteroaryl, etc.; R2 = H, alkyl; R3, R4 = independently (un)substituted alk(en/yn)yl, cycloalkyl; or NR3R4 = (un)substituted mono- or polycyclyl containing at least one heteroatom; R5 = halo/cyclo/alkyl, alkenyl, alkynyl; R6, which may be attached at N1 or N2 of the pyrazole ring = H, cycloalkyl, alk(en/yn)yl, etc.; and their tautomers, and their pharmaceutically acceptable salts] were prepared as phosphodiesterase 5 (PDE5) inhibitors. Thus, amination of 5,7-dichloro-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidine with 2-amino-4-picoline, followed by a second amination of 5-chloro intermediate with 4-piperidinemethanol gave pyrazolopyrimidine II. In a scintillation proximity PDE5 assay, II inhibited PDE5 with an IC50 value of 0.0728 nM.

IT 885472-08-2P 885472-30-0P, tert-Butyl
4-[7-[(pyrimidin-4-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperazine-1-carboxylate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(PDE5 inhibitor; preparation of pyrazolopyrimidines as PDE5 inhibitors for treating hypertension)


RN 885472-08-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-(ethoxymethyl)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

10580306


CRN 885472-07-1
CMF C25 H34 F3 N9 O4




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 885472-30-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)methyl]-3-[(2,2,2-trifluoroethoxy)methyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 792969-22-3P 792969-47-2P 792970-86-6P

794511-60-7P 794511-61-8P 794511-62-9P,
1-(2-Ethoxyethyl)-3-(methoxymethyl)-5-(piperazin-1-yl)-N-(pyrimidin-4-yl)-
1H-pyrazolo[4,3-d]pyrimidin-7-amine 885469-95-4P,
[1-[1-(2-Ethoxyethyl)-3-ethyl-7-[(4-methylpyridin-2-yl)amino]-1H-
pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-yl]methanol 885469-96-5P
885469-97-6P 885469-98-7P,
1-[1-(2-Ethoxyethyl)-3-ethyl-7-[(4-fluorophenyl)amino]-1H-pyrazolo[4,3-
d]pyrimidin-5-yl]piperidine-3-carboxamide 885469-99-8P
885470-00-8P 885470-01-9P 885470-02-0P
885470-03-1P, 1-[3-Ethyl-7-[(pyrimidin-4-yl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-
carboxamide 885470-04-2P 885470-05-3P
885470-06-4P 885470-08-6P 885470-09-7P
885470-10-0P 885470-11-1P 885470-12-2P
885470-13-3P 885470-14-4P 885470-15-5P
885470-16-6P 885470-17-7P 885470-18-8P
885470-19-9P 885470-20-2P 885470-21-3P
885470-22-4P 885470-24-6P 885470-25-7P
885470-26-8P, 3-Ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-
(pyrazin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-
d]pyrimidine-5,7-diamine 885470-27-9P 885470-28-0P,
1-[3-Ethyl-7-[(pyrazin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-
pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-carboxamide
885470-29-1P, [1-[3-Ethyl-7-[(pyrazin-2-yl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-
yl]methanol 885470-30-4P,
3-Ethyl-5-(piperazin-1-yl)-N-(pyrazin-2-yl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885470-31-5P, 3-Ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(4-
methylpyridin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-
d]pyrimidine-5,7-diamine 885470-32-6P 885470-33-7P,
1-[3-Ethyl-7-[(4-methylpyridin-2-yl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-
carboxamide 885470-34-8P,
[1-[3-Ethyl-7-[(4-methylpyridin-2-yl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-
yl]methanol 885470-35-9P,
3-Ethyl-N-(4-methylpyridin-2-yl)-5-(piperazin-1-yl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885470-36-0P 885470-37-1P 885470-38-2P,
1-[3-Ethyl-7-[(6-methylpyridin-2-yl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-
carboxamide 885470-39-3P,
[1-[3-Ethyl-7-[(6-methylpyridin-2-yl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-
yl]methanol 885470-40-6P,
3-Ethyl-N-(6-methylpyridin-2-yl)-5-(piperazin-1-yl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885470-41-7P, 3-Ethyl-N-(4-fluorophenyl)-5-(piperazin-1-yl)-1-[2-
(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885470-42-8P 885470-43-9P,
1-[3-Ethyl-7-[(pyridin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-
pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-carboxamide
885470-44-0P, [1-[3-Ethyl-7-[(pyridin-2-yl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-
yl]methanol 885470-45-1P,
3-Ethyl-5-(piperazin-1-yl)-N-(pyridin-2-yl)-1-[2-(2,2,2-

trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885470-46-2P, 3-Ethyl-N'-(4-fluorophenyl)-N-methyl-N-(1-methylpiperidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-47-3P 885470-48-4P,
 1-[3-Ethyl-7-[(4-methylpyrimidin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-carboxamide 885470-49-5P,
 [1-[3-Ethyl-7-[(4-methylpyrimidin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-yl]methanol 885470-50-8P,
 3-Ethyl-N-(4-methylpyrimidin-2-yl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885470-51-9P 885470-52-0P 885470-54-2P
 885470-55-3P, 5-(1,4-Diazepan-1-yl)-3-methyl-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885470-56-4P 885470-57-5P 885470-58-6P,
 3-Ethyl-N-(4-methylphenyl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885470-59-7P 885470-60-0P,
 3-Ethyl-N-methyl-N'-(4-methylphenyl)-N-(1-methylpiperidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885470-61-1P, N-(2-Aminoethyl)-3-ethyl-N'-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885470-62-2P 885470-63-3P,
 1-(2-Ethoxyethyl)-3-ethyl-N-(6-methylpyridin-2-yl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-64-4P
 885470-65-5P, 1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-N-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885470-66-6P 885470-67-7P 885470-68-8P
 885470-69-9P, 1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885470-70-2P 885470-71-3P 885470-72-4P
 885470-73-5P 885470-74-6P,
 5-(3,4-Dimethylpiperazin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885470-75-7P 885470-76-8P,
 N-(1-Benzylpyrrolidin-3-yl)-1-(2-ethoxyethyl)-3-ethyl-N-methyl-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-5,7-diamine
 885470-77-9P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N'-(4-methylpyridin-2-yl)-N-(1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidin-5,7-diamine 885470-78-0P,
 N-(1-Benzylpyrrolidin-3-yl)-1-(2-ethoxyethyl)-3-ethyl-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-79-1P,
 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-80-4P,
 Ethyl 4-[[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]piperidine-1-carboxylate
 885470-81-5P, 1-(2-Ethoxyethyl)-3-ethyl-5-(piperazin-1-yl)-N-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-7-amine 885470-82-6P
 , 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(5-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885470-83-7P, 1-(2-Ethoxyethyl)-3-ethyl-N-(5-methylpyridin-2-yl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-84-8P
 , 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885470-85-9P 885470-86-0P,
 1-(2-Ethoxyethyl)-3-ethyl-N'-(6-ethylpyridin-2-yl)-N-methyl-N-(1-

methylpiperidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885470-87-1P, N'-(4,6-Dimethylpyridin-2-yl)-1-(2-ethoxyethyl)-3-
 ethyl-N-methyl-N-(1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidine-
 5,7-diamine 885470-88-2P,
 1-(2-Ethoxyethyl)-3-ethyl-N'-(6-ethylpyridin-2-yl)-N-methyl-N-(1-
 methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885470-89-3P, N'-(4,6-Dimethylpyridin-2-yl)-1-(2-ethoxyethyl)-3-
 ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-
 diamine 885470-90-6P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N'-(3-
 methylphenyl)-N-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-
 diamine 885470-91-7P 885470-92-8P,
 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N'-(3-methylphenyl)-N-(1-
 methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885470-93-9P, 1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-
 N-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-95-1P
 , 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(4-
 methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885470-96-2P, 1-(2-Ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-5-
 (piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-97-3P
 885470-98-4P, 3-Methyl-N-(4-methylpyridin-2-yl)-5-(piperazin-1-yl)-
 1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885470-99-5P, 3-Methyl-5-(piperazin-1-yl)-N-(pyridin-2-yl)-1-[2-
 (2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885471-00-1P, 3-Methyl-5-(4-methylpiperazin-1-yl)-N-(6-
 methylpyridin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-
 d]pyrimidin-7-amine 885471-01-2P,
 3-Methyl-5-(4-methylpiperazin-1-yl)-N-(pyridin-2-yl)-1-[2-(2,2,2-
 trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885471-02-3P, 3-Methyl-5-(4-methylpiperazin-1-yl)-N-(4-
 methylpyridin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-
 d]pyrimidin-7-amine 885471-03-4P 885471-04-5P
 885471-05-6P 885471-06-7P,
 1-(2-Ethoxyethyl)-3-ethyl-N-(3-methylpyridin-2-yl)-5-(piperazin-1-yl)-1H-
 pyrazolo[4,3-d]pyrimidin-7-amine 885471-07-8P,
 1-(2-Ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-5-(piperazin-1-yl)-1H-
 pyrazolo[4,3-d]pyrimidin-7-amine 885471-08-9P,
 5-[[1-(2-Ethoxyethyl)-3-ethyl-5-(piperazin-1-yl)-1H-pyrazolo[4,3-
 d]pyrimidin-7-yl]amino]pyridin-2(1H)-one 885471-09-0P,
 1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-N-phenyl-1H-
 pyrazolo[4,3-d]pyrimidin-7-amine 885471-10-3P,
 1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-N-(3-methylpyridin-2-
 yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-11-4P
 885471-12-5P, 1-(2-Ethoxyethyl)-3-ethyl-N-phenyl-5-(piperazin-1-
 yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-13-6P
 885471-15-8P, 5-[[1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-
 yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]pyridin-2(1H)-one
 885471-17-0P 885471-19-2P,
 1-(2-Ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-5-(4-methylpiperazin-1-yl)-
 1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-21-6P,
 N-(3-Chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-5-(piperazin-1-yl)-1H-
 pyrazolo[4,3-d]pyrimidin-7-amine 885471-23-8P,
 1-(2-Ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-5-(piperazin-1-yl)-1H-
 pyrazolo[4,3-d]pyrimidin-7-amine 885471-24-9P,
 1-(2-Ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-5-(4-methylpiperazin-1-yl)-1H-
 pyrazolo[4,3-d]pyrimidin-7-amine 885471-26-1P,
 N-(3-Chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-1H-
 pyrazolo[4,3-d]pyrimidin-7-amine 885471-28-3P,

5-[4-(2-Aminoethyl)piperazin-1-yl]-1-(2-ethoxyethyl)-3-ethyl-N-(pyridin-2-yl)-N-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-30-7P,
5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-32-9P,
1-(2-Ethoxyethyl)-3-ethyl-N'-(6-methylpyridin-2-yl)-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-34-1P
885471-36-3P, 5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-38-5P
, 5-[4-(2-Aminoethyl)piperazin-1-yl]-1-(2-ethoxyethyl)-3-ethyl-N-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-40-9P, 5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-41-0P, 1-(2-Ethoxyethyl)-3-ethyl-N'-(4-methylpyridin-2-yl)-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885471-42-1P, 5-[4-(2-Aminoethyl)piperazin-1-yl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-7-amine
885471-43-2P, 5-[4-(Aminomethyl)piperidin-1-yl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-44-3P, 1-(2-Ethoxyethyl)-3-ethyl-N'-(4-methylpyridin-2-yl)-N-(piperidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885471-45-4P, 5-[4-(Aminomethyl)piperidin-1-yl]-1-(2-ethoxyethyl)-3-ethyl-N-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-46-5P, 5-[4-(Aminomethyl)piperidin-1-yl]-1-(2-ethoxyethyl)-3-ethyl-N-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-47-6P 885471-48-7P,
1-(2-Ethoxyethyl)-3-ethyl-N-piperidin-4-yl-N'-pyridin-2-yl-1H-pyrazolo[4,3-d]pyrimidin-5,7-diamine 885471-49-8P,
1-(2-Ethoxyethyl)-3-ethyl-N'-(6-methylpyridin-2-yl)-N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidin-5,7-diamine 885471-50-1P,
1-(2-Ethoxyethyl)-3-ethyl-N-(1-ethylpiperidin-4-yl)-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-51-2P,
1-(2-Ethoxyethyl)-3-ethyl-N-[(piperidin-4-yl)methyl]-N'-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-52-3P,
1-(2-Ethoxyethyl)-3-ethyl-N-(1-ethylpiperidin-4-yl)-N'-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-53-4P,
1-(2-Ethoxyethyl)-3-ethyl-N-(1-ethylpiperidin-4-yl)-N'-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-54-5P,
1-(2-Ethoxyethyl)-3-ethyl-N'-(6-methylpyridin-2-yl)-N-(piperidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-55-6P,
1-(2-Ethoxyethyl)-3-ethyl-N-(1-isopropylpiperidin-4-yl)-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885471-56-7P, 1-(2-Ethoxyethyl)-3-ethyl-N-(1-isopropylpiperidin-4-yl)-N'-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885471-57-8P, 1-(2-Ethoxyethyl)-3-ethyl-N-(1-isopropylpiperidin-4-yl)-N'-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885471-58-9P, 1-[1-(2-Ethoxyethyl)-3-ethyl-7-[(6-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxamide
885471-59-0P, 1-[1-(2-Ethoxyethyl)-3-ethyl-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxamide
885471-60-3P, 1-[1-(2-Ethoxyethyl)-3-ethyl-7-[(pyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxamide
885471-61-4P, 5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-62-5P, 5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-phenyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-63-6P,
5-(4-Aminopiperidin-1-yl)-N-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-64-7P,

5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-65-8P,
5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-66-9P,
1-(2-Ethoxyethyl)-3-ethyl-N'-phenyl-N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidin-5,7-diamine 885471-67-0P,
1-(2-Ethoxyethyl)-3-ethyl-N'-(3-fluorophenyl)-N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-68-1P,
1-(2-Ethoxyethyl)-3-ethyl-N'-(3-methoxyphenyl)-N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-69-2P,
1-(2-Ethoxyethyl)-3-ethyl-N'-(4-fluorophenyl)-N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-70-5P,
N'-(3-Chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-71-6P
885471-72-7P 885471-73-8P 885471-74-9P
885471-75-0P 885471-76-1P 885471-77-2P,
1-(2-Ethoxyethyl)-3-methyl-5-(4-methylpiperazin-1-yl)-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-78-3P,
5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-methyl-N-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-79-4P
885471-80-7P 885471-81-8P 885471-82-9P
885471-83-0P 885471-84-1P 885471-85-2P
885471-86-3P 885471-87-4P 885471-88-5P
885471-89-6P 885471-90-9P 885471-91-0P
885471-93-2P 885471-94-3P 885471-95-4P
885471-96-5P 885471-97-6P,
1-(2-Ethoxyethyl)-5-(4-ethylpiperazin-1-yl)-3-(methoxymethyl)-N-(pyrimidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-98-7P
885471-99-8P 885472-00-4P 885472-01-5P
885472-02-6P 885472-04-8P 885472-06-0P
885472-10-6P 885472-12-8P 885472-14-0P
885472-16-2P 885472-18-4P 885472-20-8P
885472-22-0P 885472-24-2P 885472-26-4P
885472-28-6P 885472-29-7P 885472-31-1P,
5-(Piperazin-1-yl)-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885472-32-2P 885472-33-3P 885472-34-4P,
3-[(Cyclopropylmethoxy)methyl]-5-(piperazin-1-yl)-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885472-35-5P 885472-36-6P 885472-37-7P,
5-(Piperazin-1-yl)-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(3,3,3-trifluoropropoxy)methyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885472-38-8P, 5-(1,4-Diazepan-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885472-39-9P, 5-(1,4-Diazepan-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885472-40-2P
885472-41-3P, 3-Ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885472-42-4P 885472-43-5P
885472-44-6P, 2-[4-[3-Ethyl-7-[(pyrimidin-4-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperazin-1-yl]ethanol 885472-45-7P,
5-(1,4-Diazepan-1-yl)-3-ethyl-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885472-46-8P, 3-Ethyl-5-(4-methyl-1,4-diazepan-1-yl)-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885472-47-9P 885472-48-0P 885472-49-1P

10580306

, [1-[3-Ethyl-7-[(pyrimidin-4-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-yl]methanol

885472-50-4P 885472-51-5P,

1,3-Bis(2-Ethoxyethyl)-N,N-dimethyl-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885473-18-7P

885473-19-8P 885473-20-1P 885473-21-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE5 inhibitor; preparation of pyrazolopyrimidines as PDE5 inhibitors for treating hypertension)

RN 792969-22-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-47-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10580306

RN 792970-86-6 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 794511-60-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 794511-61-8 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 794511-62-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-5-(1-piperazinyl)-N-4-pyrimidinyl-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885469-95-4 CAPLUS

CN 4-Piperidinemethanol, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methyl-2-
pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885469-96-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-(hexahydro-1H-1,4-diazepin-1-yl)-N-(4-methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885469-97-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885469-98-7 CAPLUS


CN 3-Piperidinecarboxamide, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-fluorophenyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)



RN 885469-99-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-5-(hexahydro-1H-1,4-diazepin-1-yl)-, hydrochloride (1:?) (CA INDEX NAME)

10580306



● x HCl


RN 885470-00-8 CAPLUS
CN 4-Piperidinemethanol, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-fluorophenyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)



RN 885470-01-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-5-[(3R)-3-methyl-1-piperazinyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.


10580306



● x HCl

RN 885470-02-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-
pyrimidinyl)- (CA INDEX NAME)


Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-03-1 CAPLUS
CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)

10580306



10580306



●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-06-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA
INDEX NAME)

CM 1

CRN 792969-47-2

CMF C20 H26 F3 N9 O

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.


10580306



RN 885470-08-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-09-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-4-pyrimidinyl-5-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-1-
[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.

10580306




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-10-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-(4-morpholinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-11-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-12-2 CAPLUS

CN 1-Piperazineethanol, 4-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-13-3 CAPLUS

CN 3-Piperidinecarboxamide, N,N-diethyl-1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-14-4 CAPLUS

CN 3-Piperidinemethanol, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-15-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(hexahydro-1H-1,4-diazepin-1-yl)-N4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

10580306




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-16-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-17-7 CAPLUS

CN 3-Pyrrolidinemethanol, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (1:?), (3R)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-18-8 CAPLUS

CN 3-Pyrrolidinemethanol, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-19-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(4-ethyl-1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-20-2 CAPLUS

CN Ethanone, 1-[4-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-1-piperazinyl]-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-21-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[4-(ethylsulfonyl)-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-22-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3,4-dimethyl-1-piperazinyl]-3-ethyl-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.



●_x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-24-6 CAPLUS


CN Carbamic acid, [2-[[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 885470-23-5

CMF C22 H30 F3 N9 O3

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.



RN 885470-25-7 CAPLUS

CN 1-Piperazinemethanol, 4-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-26-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-2-pyrazinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-27-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyrazinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-28-0 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-(2-pyrazinylamino)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-29-1 CAPLUS


CN 4-Piperidinemethanol, 1-[3-ethyl-7-(2-pyrazinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-30-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-(1-piperazinyl)-N-2-pyrazinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-
(CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-31-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-N5-methyl-N5-(1-methyl-4-piperidiny1)-N7-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-32-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-33-7 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-34-8 CAPLUS

CN 4-Piperidinemethanol, 1-[3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-35-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-36-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-(4-fluorophenyl)-5-[(3R)-3-methyl-1-piperazinyl]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885470-37-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-38-2 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-[(6-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-39-3 CAPLUS

CN 4-Piperidinemethanol, 1-[3-ethyl-7-[(6-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-40-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-41-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-(4-fluorophenyl)-5-(1-piperazinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



RN 885470-42-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-43-9 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-(2-pyridinylamino)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-44-0 CAPLUS


CN 4-Piperidinemethanol, 1-[3-ethyl-7-(2-pyridinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-45-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-(1-piperazinyl)-N-2-pyridinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-
(CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-46-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-N7-(4-fluorophenyl)-N5-methyl-N5-(1-methyl-4-piperidiny1)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)



RN 885470-47-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyrimidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-48-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-[(4-methyl-2-pyrimidinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-49-5 CAPLUS

CN 4-Piperidinemethanol, 1-[3-ethyl-7-[(4-methyl-2-pyrimidinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-50-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-methyl-2-pyrimidinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-51-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-52-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA
INDEX NAME)


CM 1

CRN 792969-22-3

CMF C19 H24 F3 N9 O

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.



RN 885470-54-2 CAPLUS

CN 3-Piperidinemethanol, 1-[3-methyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-55-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(hexahydro-1H-1,4-diazepin-1-yl)-3-methyl-N-4-pyrimidinyl-1-[2-(2,2,2-

10580306

trifluoroethoxy)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 885470-56-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(hexahydro-1H-1,4-diazepin-1-yl)-3-methyl-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA
INDEX NAME)

CM 1

CRN 885470-55-3

CMF C19 H24 F3 N9 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.

10580306



RN 885470-57-5 CAPLUS


CN 4-Piperidinemethanol, 1-[3-methyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-58-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-(4-methylphenyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




RN 885470-59-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-(4-methylphenyl)-5-[(3R)-3-methyl-1-piperazinyl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306

Absolute stereochemistry.




RN 885470-60-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-N5-methyl-N7-(4-methylphenyl)-N5-(1-methyl-4-piperidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)



RN 885470-61-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(2-aminoethyl)-3-ethyl-N7-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-62-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-
pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-63-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)- (CA
INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-64-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3S)-3-methyl-1-piperazinyl]-N-(6-methyl-2-
pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-65-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-N-(6-methyl-2-
pyridinyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-66-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(6-
methyl-2-pyridinyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-67-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl-
(CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-68-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3S)-3-methyl-1-piperazinyl]-N-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-69-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-N-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-70-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(5-methyl-2-
pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-71-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(6-ethyl-2-pyridinyl)-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-72-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-73-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-74-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,4-dimethyl-1-piperazinyl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-75-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-(1-methyl-4-piperidinyl)-N7-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-76-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-N5-[1-(phenylmethyl)-3-pyrrolidinyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-77-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-N5-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-78-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-(4-methyl-2-pyridinyl)-N5-[1-(phenylmethyl)-3-
pyrrolidinyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-79-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-2-
pyridinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-80-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, ethyl ester
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-81-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-(1-piperazinyl)-N-2-pyridinyl- (CA INDEX
NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-82-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-83-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-84-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(6-
methyl-2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-85-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-
methyl-2-pyridinyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-86-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-(6-ethyl-2-pyridinyl)-N5-methyl-N5-(1-methyl-
4-piperidinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-87-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-
methyl-3-pyrrolidinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-88-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-(6-ethyl-2-pyridinyl)-N5-methyl-N5-(1-methyl-
3-pyrrolidinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-89-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-
methyl-4-piperidinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-90-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(3-methylphenyl)-N5-(1-methyl-4-
piperidinyl)- (CA INDEX NAME)




RN 885470-91-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(3-methylphenyl)-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.

10580306



RN 885470-92-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(3-methylphenyl)-N5-(1-methyl-3-
pyrrolidinyl)- (CA INDEX NAME)



RN 885470-93-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-N-2-pyridinyl- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-95-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(4-methyl-2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-96-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)- (CA
INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-97-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-98-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-99-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-(1-piperazinyl)-N-2-pyridinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-00-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-(4-methyl-1-piperazinyl)-N-(6-methyl-2-pyridinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-01-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-(4-methyl-1-piperazinyl)-N-2-pyridinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-02-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-(4-methyl-1-piperazinyl)-N-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-03-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(3-methyl-2-
pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-04-5 CAPLUS

CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-
piperazinyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)


Absolute stereochemistry.

10580306




RN 885471-05-6 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-phenyl- (CA
INDEX NAME)

Absolute stereochemistry.




RN 885471-06-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(3-methyl-2-pyridinyl)-5-(1-piperazinyl)- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10580306


RN 885471-07-8 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-5-(1-piperazinyl)- (CA INDEX
NAME)



RN 885471-08-9 CAPLUS
CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-3-ethyl-5-(1-piperazinyl)-1H-
pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 885471-09-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-N-phenyl- (CA INDEX
NAME)



10580306


RN 885471-10-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-N-(3-methyl-2-
pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 885471-11-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 885471-12-5 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-phenyl-5-(1-piperazinyl)- (CA INDEX NAME)


10580306



RN 885471-13-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 885471-15-8 CAPLUS

CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-
1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 885471-17-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,


10580306

1-(2-ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-5-[(3R)-3-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885471-19-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-5-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)




RN 885471-21-6 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-5-(1-piperazinyl)- (CA INDEX
NAME)

10580306




RN 885471-23-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-5-(1-piperazinyl)- (CA
INDEX NAME)




RN 885471-24-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-5-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)




10580306

RN 885471-26-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)




RN 885471-28-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[4-(2-aminoethyl)-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-2-pyridinyl-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-30-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-32-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-(6-methyl-2-pyridinyl)-N5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-34-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-2-pyridinyl-, rel- (CA INDEX NAME)

Relative stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-36-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-2-pyridinyl- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-38-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[4-(2-aminoethyl)-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(6-methyl-2-
pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-40-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-(6-methyl-2-
pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-41-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-(4-methyl-2-pyridinyl)-N5-[2-(4-
morpholinyl)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-42-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[4-(2-aminoethoxy)-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-43-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[4-(aminomethyl)-1-piperidinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-44-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-(4-methyl-2-pyridinyl)-N5-4-piperidinyl- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-45-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[4-(aminomethyl)-1-piperidinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(6-methyl-2-
pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-46-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[4-(aminomethyl)-1-piperidinyl]-1-(2-ethoxyethyl)-3-ethyl-N-2-pyridinyl-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-47-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-(4-methyl-2-pyridinyl)-N5-(4-
piperidinylmethyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-48-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-4-piperidinyl-N7-2-pyridinyl- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-49-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-(6-methyl-2-pyridinyl)-N5-(4-
piperidinylmethyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-50-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-(1-ethyl-4-piperidinyl)-N7-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-51-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-(4-piperidinylmethyl)-N7-2-pyridinyl- (CA
INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-52-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-(1-ethyl-4-piperidiny1)-N7-2-pyridiny1- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-53-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-(1-ethyl-4-piperidiny1)-N7-(6-methyl-2-
pyridiny1)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-54-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-(6-methyl-2-pyridiny1)-N5-4-piperidiny1- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-55-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-[1-(1-methylethyl)-4-piperidinyl]-N7-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-56-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-[1-(1-methylethyl)-4-piperidinyl]-N7-2-
pyridinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-57-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-[1-(1-methylethyl)-4-piperidinyl]-N7-(6-
methyl-2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-58-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(6-methyl-2-
pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-59-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-60-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[1-(2-ethoxyethyl)-3-ethyl-7-(2-pyridinylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 885471-61-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-
(CA INDEX NAME)



RN 885471-62-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-phenyl- (CA INDEX
NAME)




RN 885471-63-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-amino-1-piperidinyl)-N-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-


10580306

(CA INDEX NAME)



RN 885471-64-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-
(CA INDEX NAME)




RN 885471-65-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-
(CA INDEX NAME)


10580306



RN 885471-66-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-phenyl-N5-(4-piperidinylmethyl)- (CA INDEX
NAME)




RN 885471-67-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-(3-fluorophenyl)-N5-(4-piperidinylmethyl)-
(CA INDEX NAME)




RN 885471-68-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,

10580306

1-(2-ethoxyethyl)-3-ethyl-N7-(3-methoxyphenyl)-N5-(4-piperidinylmethyl)-
(CA INDEX NAME)




RN 885471-69-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N7-(4-fluorophenyl)-N5-(4-piperidinylmethyl)-
(CA INDEX NAME)



RN 885471-70-5 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-N5-(4-piperidinylmethyl)-
(CA INDEX NAME)


10580306



RN 885471-71-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl-
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-72-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-(4-methyl-1-piperazinyl)-N-(6-methyl-2-
pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-73-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-(4-methyl-1-piperazinyl)-N-2-pyridinyl- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-74-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-(1-piperazinyl)-N-2-pyridinyl- (CA INDEX
NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-75-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-76-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-77-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-(4-methyl-1-piperazinyl)-N-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-78-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-methyl-N-(6-methyl-2-
pyridinyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-79-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-
(methoxymethyl)-N-2-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-80-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-2-
pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-81-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-
(ethoxymethyl)-N-2-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-82-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-2-
pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-83-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-84-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-85-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(4-fluorophenyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885471-86-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-
(ethoxymethyl)-N-(4-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 885471-87-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-(4-fluorophenyl)-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885471-88-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-
methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-89-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-(ethoxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-90-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-91-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-(methoxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-93-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(6-ethyl-2-pyridinyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-94-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-N-(6-ethyl-2-
pyridinyl)-3-(methoxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-95-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-(6-ethyl-2-pyridinyl)-5-[(3R)-3-
methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-96-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-1-(2-propoxyethyl)-N-2-
pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-97-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-(4-ethyl-1-piperazinyl)-3-(methoxymethyl)-N-4-
pyrimidinyl- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-98-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-
1-(2-propoxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-99-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-(ethoxymethyl)-N-(6-methyl-2-
pyridinyl)-1-(2-propoxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-00-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-((1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl)-3-(ethoxymethyl)-1-(2-
propoxyethyl)-N-2-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-01-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-
1-(2-propoxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-02-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S, 4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxymethyl)-3-
(ethoxymethyl)-N-(6-ethyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-04-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-
(2,2,2-trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX
NAME)


CM 1

CRN 885472-03-7

10580306

CMF C21 H28 F3 N9 O2

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 885472-06-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-(ethoxymethyl)-N-4-
pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate
(1:?) (CA INDEX NAME)


CM 1

CRN 885472-05-9

CMF C21 H26 F3 N9 O2

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 885472-10-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(ethoxymethyl)-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 885472-09-3

CMF C20 H26 F3 N9 O2




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 885472-12-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(ethoxymethyl)-5-(4-methyl-1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 885472-11-7

CMF C21 H28 F3 N9 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 885472-14-0 CAPLUS


10580306

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-[2-(dimethylamino)ethyl]-3-(ethoxymethyl)-N5-methyl-N7-4-pyrimidinyl-1-
[2-(2,2,2-trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX
NAME)

CM 1

CRN 885472-13-9

CMF C21 H30 F3 N9 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 885472-16-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-(ethoxymethyl)-N7-4-pyrimidinyl-N5-(2,2,6,6-tetramethyl-4-piperidinyl)-1-
[2-(2,2,2-trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX
NAME)

CM 1

CRN 885472-15-1

CMF C25 H36 F3 N9 O2

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 885472-18-4 CAPLUS

CN 4-Piperidinol, 1-[3-(ethoxymethyl)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 885472-17-3

CMF C21 H27 F3 N8 O3




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 885472-20-8 CAPLUS

CN 4-Piperidinemethanol, 1-[3-(ethoxymethyl)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 885472-19-5

CMF C22 H29 F3 N8 O3




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 885472-22-0 CAPLUS

10580306


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(1-methylethoxy)methyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
1-[2-(2,2,2-trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA
INDEX NAME)

CM 1

CRN 885472-21-9

CMF C22 H30 F3 N9 O2

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 885472-24-2 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[3-[(1-methylethoxy)methyl]-7-(4-
pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-
d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester, 2,2,2-trifluoroacetate (1:?)
(CA INDEX NAME)

CM 1

CRN 885472-23-1

CMF C26 H36 F3 N9 O4

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 885472-26-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(1-methylethoxy)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 885472-25-3

CMF C21 H28 F3 N9 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10580306

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 885472-28-6 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(3,3,3-trifluoropropoxy)methyl]-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 885472-27-5
CMF C22 H27 F6 N9 O2


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



10580306


RN 885472-29-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-31-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-
[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-32-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-33-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(cyclopropylmethoxy)methyl]-5-[(3S)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-34-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(cyclopropylmethoxy)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-35-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(cyclopropylmethoxy)methyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-36-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-3-[(4,4,4-
trifluorobutoxy)methyl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX
NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-37-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-
[(3,3,3-trifluoropropoxy)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-38-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-(hexahydro-1H-1,4-diazepin-1-yl)-N-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-39-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-5-(hexahydro-1H-1,4-diazepin-
1-yl)- (CA INDEX NAME)




RN 885472-40-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.

10580306



RN 885472-41-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-42-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3S)-3-methyl-1-piperazinyl]-N4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-43-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-4-pyrimidinyl-5-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-1-
[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-44-6 CAPLUS

CN 1-Piperazineethanol, 4-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-45-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-(hexahydro-1H-1,4-diazepin-1-yl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-46-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-4-pyrimidinyl-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-47-9 CAPLUS

CN 3-Pyrrolidinemethanol, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-48-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R)-3,4-dimethyl-1-piperazinyl]-3-ethyl-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-49-1 CAPLUS

CN 4-Piperidinemethanol, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-50-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-methyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-51-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1,3-bis(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-18-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-(1-piperazinyl)-N-2-pyrazinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-
, hydrochloride (1:?) (CA INDEX NAME)

10580306




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-19-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(4-methyl-2-pyridinyl)-1-
[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-20-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-1-[2-
(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-21-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-(4-fluorophenyl)-5-(1-piperazinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

IT 885473-22-3P 885473-23-4P 885473-24-5P

885473-25-6P 885473-26-7P 885473-28-9P

885473-29-0P 885473-30-3P 885473-31-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(PDE5 inhibitor; preparation of pyrazolopyrimidines as PDE5 inhibitors for
treating hypertension)

10580306

RN 885473-22-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-23-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-(1-piperazinyl)-N-2-pyridinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-
, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-24-5 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-N7-(4-fluorophenyl)-N5-methyl-N5-(1-methyl-4-piperidinyl)-1-[2-

10580306

(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 885473-25-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyrimidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-26-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-(4-methyl-2-pyrimidinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

10580306




●_x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-28-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-(4-methylphenyl)-5-(1-piperazinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)




●_x HCl

RN 885473-29-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-N-(4-methylphenyl)-5-[(3R)-3-methyl-1-piperazinyl]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)


Absolute stereochemistry.

10580306



●x HCl


RN 885473-30-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-N5-methyl-N7-(4-methylphenyl)-N5-(1-methyl-4-piperidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 885473-31-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(3-methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 1044713-68-9 1044713-69-0 1044713-70-3
 1044713-71-4 1044713-74-7 1044713-75-8
 1044713-76-9 1044713-77-0 1044713-78-1
 1044713-79-2 1044713-80-5 1044713-82-7
 1044713-83-8 1044713-84-9 1044713-85-0
 1044713-86-1 1044713-87-2 1044713-88-3
 1044713-89-4 1044713-90-7 1044713-91-8
 1044713-92-9 1044713-93-0 1044713-94-1
 1044713-95-2 1044713-97-4 1044713-98-5
 1044713-99-6 1044714-00-2 1044714-01-3
 1044714-02-4 1044714-03-5 1044714-04-6
 1044714-05-7 1044714-06-8 1044714-07-9
 1044714-08-0 1044714-09-1 1044714-10-4
 1044714-11-5 1044714-12-6 1044714-13-7
 1044714-14-8 1044714-15-9 1044714-16-0
 1044714-17-1 1044714-18-2 1044714-19-3
 1044714-20-6 1044714-21-7 1044714-22-8
 1044714-23-9 1044714-24-0 1044714-25-1
 1044714-26-2 1044714-27-3 1044714-28-4
 1044714-29-5 1044714-30-8 1044714-31-9
 1044714-32-0 1044714-33-1 1044714-34-2
 1044714-35-3 1044714-36-4 1044714-37-5
 1044714-38-6 1044714-39-7 1044714-42-2
 1044714-43-3 1044714-44-4 1044714-45-5
 1044714-46-6 1044714-47-7 1044714-48-8
 1044714-49-9 1044714-50-2 1044714-51-3
 1044714-52-4 1044714-53-5 1044714-54-6
 1044714-55-7 1044714-56-8 1044714-57-9
 1044714-59-1 1044714-60-4 1044714-61-5
 1044714-62-6 1044714-63-7 1044714-64-8
 1044714-66-0 1044714-68-2 1044714-69-3
 1044714-70-6 1044714-72-8 1044714-73-9
 1044714-74-0 1044714-75-1 1044714-77-3


RL: PRPH (Prophetic)

(Preparation of novel 5,7-diaminopyrazolo[4,3-d]pyrimidines as PDE5 inhibitors for treating hypertension)

10580306


RN 1044713-68-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-3-[1-(2,2,2-
trifluoroethoxy)ethyl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX
NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-69-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[2-(cyclopropyloxy)ethyl]-1-(2-ethoxyethyl)-5-(1-piperazinyl)-N-4-
pyrimidinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-70-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[[1-methylcyclopropyl)methoxy]methyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-
4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-71-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-ethanol,
5-(dimethylamino)-1-(2-ethoxyethyl)- α -(1-methylethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-74-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-ethanol,
 α -cyclopentyl-5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-
 pyridinyl)amino]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-75-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-76-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-77-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[1-(1-methylethoxy)ethyl]-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-78-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(2,5-dimethyl-1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-79-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[3-(cyclohexyloxy)pentyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-80-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-82-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-83-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyridinyl-3-[(3,3,3-
trifluoropropoxy)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044713-84-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[2-(1-methylethoxy)ethyl]-N7-(4-methyl-
2-pyridinyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-85-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-[2-(cyclopropylmethoxy)ethyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyridinyl-3-[(3,3,3-trifluoropropoxy)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044713-86-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(2-methoxyethoxy)methyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-87-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[4-[(dimethylamino)methyl]-1-piperidinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-88-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(2-ethoxyethoxy)methyl]-1-(2-ethoxyethyl)-5-(1-piperazinyl)-N-4-
pyrimidinyl- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-89-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1,3-bis[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-90-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1-piperazinyl)-N-2-pyridinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-
[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)

CC1=CN(C2=CN(C3=CN(C4=CN(C5=CC=C4N(C5)C6=CC=CC=C6N6)C7=CC=CC=C7N7)C8=CC=CC=C8N8)C9=CC=CC=C9N9)C10=CC=CC=C10N10)C11=CC=CC=C11N11)C12=CC=CC=C12N12)C13=CC=CC=C13N13)C14=CC=CC=C14N14)C15=CC=CC=C15N15)C16=CC=CC=C16N16)C17=CC=CC=C17N17)C18=CC=CC=C18N18)C19=CC=CC=C19N19)C20=CC=CC=C20N20)C21=CC=CC=C21N21)C22=CC=CC=C22N22)C23=CC=CC=C23N23)C24=CC=CC=C24N24)C25=CC=CC=C25N25)C26=CC=CC=C26N26)C27=CC=CC=C27N27)C28=CC=CC=C28N28)C29=CC=CC=C29N29)C30=CC=CC=C30N30)C31=CC=CC=C31N31)C32=CC=CC=C32N32)C33=CC=CC=C33N33)C34=CC=CC=C34N34)C35=CC=CC=C35N35)C36=CC=CC=C36N36)C37=CC=CC=C37N37)C38=CC=CC=C38N38)C39=CC=CC=C39N39)C40=CC=CC=C40N40)C41=CC=CC=C41N41)C42=CC=CC=C42N42)C43=CC=CC=C43N43)C44=CC=CC=C44N44)C45=CC=CC=C45N45)C46=CC=CC=C46N46)C47=CC=CC=C47N47)C48=CC=CC=C48N48)C49=CC=CC=C49N49)C50=CC=CC=C50N50)C51=CC=CC=C51N51)C52=CC=CC=C52N52)C53=CC=CC=C53N53)C54=CC=CC=C54N54)C55=CC=CC=C55N55)C56=CC=CC=C56N56)C57=CC=CC=C57N57)C58=CC=CC=C58N58)C59=CC=CC=C59N59)C60=CC=CC=C60N60)C61=CC=CC=C61N61)C62=CC=CC=C62N62)C63=CC=CC=C63N63)C64=CC=CC=C64N64)C65=CC=CC=C65N65)C66=CC=CC=C66N66)C67=CC=CC=C67N67)C68=CC=CC=C68N68)C69=CC=CC=C69N69)C70=CC=CC=C70N70)C71=CC=CC=C71N71)C72=CC=CC=C72N72)C73=CC=CC=C73N73)C74=CC=CC=C74N74)C75=CC=CC=C75N75)C76=CC=CC=C76N76)C77=CC=CC=C77N77)C78=CC=CC=C78N78)C79=CC=CC=C79N79)C80=CC=CC=C80N80)C81=CC=CC=C81N81)C82=CC=CC=C82N82)C83=CC=CC=C83N83)C84=CC=CC=C84N84)C85=CC=CC=C85N85)C86=CC=CC=C86N86)C87=CC=CC=C87N87)C88=CC=CC=C88N88)C89=CC=CC=C89N89)C90=CC=CC=C90N90)C91=CC=CC=C91N91)C92=CC=CC=C92N92)C93=CC=CC=C93N93)C94=CC=CC=C94N94)C95=CC=CC=C95N95)C96=CC=CC=C96N96)C97=CC=CC=C97N97)C98=CC=CC=C98N98)C99=CC=CC=C99N99)C100=CC=CC=C100N100)C101=CC=CC=C101N101)C102=CC=CC=C102N102)C103=CC=CC=C103N103)C104=CC=CC=C104N104)C105=CC=CC=C105N105)C106=CC=CC=C106N106)C107=CC=CC=C107N107)C108=CC=CC=C108N108)C109=CC=CC=C109N109)C110=CC=CC=C110N110)C111=CC=CC=C111N111)C112=CC=CC=C112N112)C113=CC=CC=C113N113)C114=CC=CC=C114N114)C115=CC=CC=C115N115)C116=CC=CC=C116N116)C117=CC=CC=C117N117)C118=CC=CC=C118N118)C119=CC=CC=C119N119)C120=CC=CC=C120N120)C121=CC=CC=C121N121)C122=CC=CC=C122N122)C123=CC=CC=C123N123)C124=CC=CC=C124N124)C125=CC=CC=C125N125)C126=CC=CC=C126N126)C127=CC=CC=C127N127)C128=CC=CC=C128N128)C129=CC=CC=C129N129)C130=CC=CC=C130N130)C131=CC=CC=C131N131)C132=CC=CC=C132N132)C133=CC=CC=C133N133)C134=CC=CC=C134N134)C135=CC=CC=C135N135)C136=CC=CC=C136N136)C137=CC=CC=C137N137)C138=CC=CC=C138N138)C139=CC=CC=C139N139)C140=CC=CC=C140N140)C141=CC=CC=C141N141)C142=CC=CC=C142N142)C143=CC=CC=C143N143)C144=CC=CC=C144N144)C145=CC=CC=C145N145)C146=CC=CC=C146N146)C147=CC=CC=C147N147)C148=CC=CC=C148N148)C149=CC=CC=C149N149)C150=CC=CC=C150N150)C151=CC=CC=C151N151)C152=CC=CC=C152N152)C153=CC=CC=C153N153)C154=CC=CC=C154N154)C155=CC=CC=C155N155)C156=CC=CC=C156N156)C157=CC=CC=C157N157)C158=CC=CC=C158N158)C159=CC=CC=C159N159)C160=CC=CC=C160N160)C161=CC=CC=C161N161)C162=CC=CC=C162N162)C163=CC=CC=C163N163)C164=CC=CC=C164N164)C165=CC=CC=C165N165)C166=CC=CC=C166N166)C167=CC=CC=C167N167)C168=CC=CC=C168N168)C169=CC=CC=C169N169)C170=CC=CC=C170N170)C171=CC=CC=C171N171)C172=CC=CC=C172N172)C173=CC=CC=C173N173)C174=CC=CC=C174N174)C175=CC=CC=C175N175)C176=CC=CC=C176N176)C177=CC=CC=C177N177)C178=CC=CC=C178N178)C179=CC=CC=C179N179)C180=CC=CC=C180N180)C181=CC=CC=C181N181)C182=CC=CC=C182N182)C183=CC=CC=C183N183)C184=CC=CC=C184N184)C185=CC=CC=C185N185)C186=CC=CC=C186N186)C187=CC=CC=C187N187)C188=CC=CC=C188N188)C189=CC=CC=C189N189)C190=CC=CC=C190N190)C191=CC=CC=C191N191)C192=CC=CC=C192N192)C193=CC=CC=C193N193)C194=CC=CC=C194N194)C195=CC=CC=C195N195)C196=CC=CC=C196N196)C197=CC=CC=C197N197)C198=CC=CC=C198N198)C199=CC=CC=C199N199)C200=CC=CC=C200N200)C201=CC=CC=C201N201)C202=CC=CC=C202N202)C203=CC=CC=C203N203)C204=CC=CC=C204N204)C205=CC=CC=C205N205)C206=CC=CC=C206N206)C207=CC=CC=C207N207)C208=CC=CC=C208N208)C209=CC=CC=C209N209)C210=CC=CC=C210N210)C211=CC=CC=C211N211)C212=CC=CC=C212N212)C213=CC=CC=C213N213)C214=CC=CC=C214N214)C215=CC=CC=C215N215)C216=CC=CC=C216N216)C217=CC=CC=C217N217)C218=CC=CC=C218N218)C219=CC=CC=C219N219)C220=CC=CC=C220N220)C221=CC=CC=C221N221)C222=CC=CC=C222N222)C223=CC=CC=C223N223)C224=CC=CC=C224N224)C225=CC=CC=C225N225)C226=CC=CC=C226N226)C227=CC=CC=C227N227)C228=CC=CC=C228N228)C229=CC=CC=C229N229)C230=CC=CC=C230N230)C231=CC=CC=C231N231)C232=CC=CC=C232N232)C233=CC=CC=C233N233)C234=CC=CC=C234N234)C235=CC=CC=C235N235)C236=CC=CC=C236N236)C237=CC=CC=C237N237)C238=CC=CC=C238N238)C239=CC=CC=C239N239)C240=CC=CC=C240N240)C241=CC=CC=C241N241)C242=CC=CC=C242N242)C243=CC=CC=C243N243)C244=CC=CC=C244N244)C245=CC=CC=C245N245)C246=CC=CC=C246N246)C247=CC=CC=C247N247)C248=CC=CC=C248N248)C249=CC=CC=C249N249)C250=CC=CC=C250N250)C251=CC=CC=C251N251)C252=CC=CC=C252N252)C253=CC=CC=C253N253)C254=CC=CC=C254N254)C255=CC=CC=C255N255)C256=CC=CC=C256N256)C257=CC=CC=C257N257)C258=CC=CC=C258N258)C259=CC=CC=C259N259)C260=CC=CC=C260N260)C261=CC=CC=C261N261)C262=CC=CC=C

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-[2-(cyclohexylmethoxy)ethyl]-1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)




CN INDEX NAME NOT YET ASSIGNED



RN 1044713-93-0 CAPLUS

10580306


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-[2-(cyclopropylmethoxy)ethyl]-1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-94-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-ethyl-N5-methyl-N7-2-pyridinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-
[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-95-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,3-dimethyl-1-piperazinyl)-3-[(1-methylethoxy)methyl]-N-4-pyrimidinyl-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-97-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-[2-(cyclopropylmethoxy)ethyl]-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-
piperazinyl]-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-98-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[2-(2-methylpropoxy)ethyl]-N7-(4-methyl-
2-pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044713-99-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-[2-(2-methylpropoxy)ethyl]-5-(1-piperazinyl)-N-4-
pyrimidinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-00-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-3-[1-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-01-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-02-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-[2-(cyclopropylmethoxy)ethyl]-3-[(cyclopropylmethoxy)methyl]-5-[(3R)-3-
methyl-1-piperazinyl]-N-4-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.

10580306



RN 1044714-03-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,3-dimethyl-1-piperazinyl)-3-[(2-methylpropoxy)methyl]-N-4-pyrimidinyl-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-04-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-[2-(1-methylethoxy)ethyl]-5-(1-piperazinyl)-N-4-
pyrimidinyl- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-05-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1,3-bis(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-06-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-3-[(2-methylpropoxy)methyl]-N-4-
pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-07-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-08-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[2-(cyclohexylmethoxy)ethyl]-1-(2-ethoxyethyl)-5-(1-piperazinyl)-N-4-
pyrimidinyl- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-09-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(1-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-10-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-11-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-3-(propoxymethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-12-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[2-(cyclopropylmethoxy)ethyl]-1-(2-ethoxyethyl)-5-(1-piperazinyl)-N-4-pyrimidinyl- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-13-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(1-ethoxyethyl)-1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-14-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(cyclobutylmethoxy)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-15-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(cyclopropylethoxymethyl)-1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-
piperazinyl]-N-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-16-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(cyclohexylmethoxy)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-17-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,N5-dimethyl-3-[2-(1-methylethoxy)ethyl]-N7-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-18-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[[[1-methylcyclopropyl)methoxy]methyl]-5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-19-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-ethanol,
 α -cyclopropyl-5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-20-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-ethanol,
5-(dimethylamino)- α -ethenyl-1-(2-ethoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-21-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-22-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-amino-1-piperidinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-23-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(1-ethoxy-2-methylpropyl)-N-(4-methyl-2-pyridinyl)-5-
(1-piperazinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 1044714-24-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[3-(cyclopropylmethoxy)pentyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

CC(C)C(=O)OCC1=CN(C2=CN(C3=CC=CC=C3)N(C4=CC=CC=C4)N2)N(C5=CC=CC=C5)N1


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[1-(2-ethoxyethoxy)ethyl]-1-(2-ethoxyethyl)-5-(1-piperazinyl)-N-4-
pyrimidinyl- (CA INDEX NAME)



CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-3-[1-(2-
methylpropoxy)propyl]-N-4-pyrimidinyl- (CA INDEX NAME)

Page 303


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-27-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-methyl-1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-28-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[3-(cyclopropyloxy)pentyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-29-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,3-dimethyl-1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-30-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(2-ethoxyethoxy)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-31-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[3-(2,2,2-trifluoroethoxy)pentyl]- (CA INDEX
NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-32-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-33-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,3-dimethyl-1-piperazinyl)-3-(ethoxymethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-34-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-[(2-methoxyethoxy)methyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-35-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[3-(1-methylethoxy)pentyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-36-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[4-(aminomethyl)-1-piperidinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-37-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1-piperazinyl)-3-(propoxymethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-38-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-39-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[2-[(1-methylcyclopropyl)methoxy]ethyl]-
N7-(4-methyl-2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-42-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-(2-methoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-43-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,3-dimethyl-1-piperazinyl)-N-2-pyridinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-44-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-
3-[(3,3,3-trifluoropropoxy)methyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-45-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-[2-(cyclopropyloxy)ethyl]-1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-
2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-46-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-[2-(cyclopropylmethoxy)ethyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-
methyl-2-pyridinyl)-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-47-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-48-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[2-(2,2-dimethylpropoxy)ethyl]-1-(2-ethoxyethyl)-5-(1-piperazinyl)-N-4-
pyrimidinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-49-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-[2-(2,2-dimethylpropoxy)ethyl]-1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-50-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-[2-(cyclopropylmethoxy)ethyl]-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 1044714-51-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-52-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(2-methoxyethyl)-5-(1-piperazinyl)-N-4-pyrimidinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-53-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-methyl-1-piperazinyl)-N-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-54-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-55-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(2-methylpropoxy)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-56-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-[2-(cyclopropylmethoxy)ethyl]-3-[(cyclopropylmethoxy)methyl]-5-[(3R)-3-
methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-57-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3S)-3-methyl-1-piperazinyl]-3-[(2-methylpropoxy)methyl]-N-4-
pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-59-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-(1-piperazinyl)-N-4-pyrimidinyl-3-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-60-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3S)-3-methyl-1-piperazinyl]-3-(propoxymethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-61-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-[2-[(1-methylcyclopropyl)methoxy]ethyl]-5-(1-piperazinyl)-N-4-pyrimidinyl- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-62-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-
3-[1-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-63-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[[[(1-methylcyclopropyl)methoxy]methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-64-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-66-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(cyclopentylmethoxy)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-68-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-3-[3-(2-methylpropoxy)pentyl]-N-4-
pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-69-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-[2-(cyclopropyloxy)ethyl]-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-70-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(cycloheptylmethoxy)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-72-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-[1-(2-methoxyethoxy)ethyl]-5-[(3R)-3-methyl-1-
piperazinyl]-N-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-73-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-74-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,3-dimethyl-1-piperazinyl)-3-(propoxymethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-75-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[1-(2-ethoxyethoxy)ethyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044714-77-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 792968-79-7P, [5-Dimethylamino-1-(2-ethoxyethyl)-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol
866923-52-6P, 5-Dimethylamino-1-(2-ethoxyethyl)-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidine-3-carboxaldehyde
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazolopyrimidines as PDE5 inhibitors for treating hypertension)
RN 792968-79-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-52-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxaldehyde,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 1076232-97-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrazolopyrimidines as PDE5 inhibitors for treating
hypertension)

RN 1076232-97-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(ethoxymethyl)-5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:151143 CAPLUS
 DOCUMENT NUMBER: 144:219321
 TITLE: Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor
 INVENTOR(S): Hughes, Bernadette
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006016262	A1	20060216	WO 2005-IB2457	20050729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005270904	A1	20060216	AU 2005-270904	20050729
CA 2575980	A1	20060216	CA 2005-2575980	20050729
EP 1778241	A1	20070502	EP 2005-769508	20050729
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101001630	A	20070718	CN 2005-80027106	20050729
JP 2008509900	T	20080403	JP 2007-525380	20050729
BR 2005014296	A	20080617	BR 2005-14296	20050729
NO 2006006059	A	20070129	NO 2006-6059	20061229
IN 2007DN00233	A	20070803	IN 2007-DN233	20070109
MX 200700694	A	20070312	MX 2007-694	20070118
KR 2007036171	A	20070402	KR 2007-703231	20070209
KR 2008064911	A	20080709	KR 2008-715060	20080620
PRIORITY APPLN. INFO.:			GB 2004-17777	A 20040810
			US 2004-606302P	P 20040831
			EP 2004-107777	A 20040810
			WO 2005-IB2457	W 20050729
			KR 2007-703231	A3 20070209

AB The present invention relates to a combination of a selective noradrenaline reuptake inhibitor (NRI) and a phosphodiesterase type 5 (PDEV) inhibitor. Such a combination is particularly useful in the treatment of pain. For example, the combination of i.p. (S,S)-reboxetine succinate and s.c. PDEV inhibitor 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulfonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Compound A) displayed synergy in animal models of pain. Following single administration both (S,S)-reboxetine and Compound A produced a dose dependent anti-allodynic effect in the preclin. model of chronic pain.

10580306


IT 792969-47-2 853003-47-1 853003-48-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(combination of selective noradrenaline reuptake inhibitor and PDEV
inhibitor in treatment of pain)
RN 792969-47-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853003-47-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-48-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT:


5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10580306

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1130641 CAPLUS
DOCUMENT NUMBER: 143:387058
TITLE: Preparation of substituted pyrazolo[4,3-d]pyrimidines
as inhibitors of phosphodiesterase V
INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Fox, David
Nathan Abraham; Lu, Hwang-Fun; Marsh, Ian Roger;
Morrell, Andrew Ian; Owen, Dafydd Rhys; Palmer,
Michael John; Rogers, Thomas Edward; Windslow, Carol
Ann
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097799	A1	20051020	WO 2005-IB891	20050330
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2562251	A1	20051020	CA 2005-2562251	20050330
EP 1742950	A1	20070117	EP 2005-718362	20050330
EP 1742950	B1	20081217		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
BR 2005009731	A	20070925	BR 2005-9731	20050330
JP 2007532526	T	20071115	JP 2007-506858	20050330
MX 2006PA10554	A	20061208	MX 2006-PA10554	20060914
US 20080293697	A1	20081127	US 2006-599702	20061219
PRIORITY APPLN. INFO.:			GB 2004-7927	A 20040407
			GB 2004-7946	A 20040407
			US 2004-572024P	P 20040518
			US 2004-572049P	P 20040518
			WO 2005-IB891	W 20050330
OTHER SOURCE(S):	CASREACT 143:387058; MARPAT 143:387058			
GI				



AB Title compds. I [R1 = cycloalkyl, cycloalkenyl, 5-6 membered heteroarom. ring, etc.; R2 = H, alkyl; R3-4 = alk(en/yn)yl, cycloalkyl, etc.; R5 = amino, alkylenylamino, etc.; R6 = alkyl, haloalkyl, alkenyl, alkynyl, etc.] are prepared For instance II is prepared in 12 steps from di-Me 4-nitro-1H-pyrazole-3,5-dicarboxylate, 2-ethoxyethyl bromide, 2-amino-4-methylpyridine, dimethylaminoacetic acid and dimethylamine. II has an IC₅₀ = 1.12 for phosphodiesterase 5 (PDE5). I are useful for the treatment of diabetes and hypertension.

IT 1044708-68-0 1044708-69-1 1044708-74-8
 1044708-75-9 1044708-76-0 1044708-77-1
 1044708-82-8 1044708-83-9 1044708-84-0
 1044708-85-1 1044708-90-8 1044708-91-9
 1044708-92-0 1044708-93-1 1044708-99-7
 1044709-00-3 1044709-01-4 1044709-06-9
 1044709-07-0 1044709-08-1 1044709-09-2
 1044709-14-9 1044709-15-0 1044709-16-1
 1044709-17-2 1044709-22-9 1044709-23-0
 1044709-24-1 1044709-25-2 1044709-29-6
 1044709-30-9 1044709-31-0 1044709-32-1
 1044709-36-5 1044709-37-6 1044709-39-8
 1044709-40-1 1044709-43-4 1044709-44-5
 1044709-46-7 1044709-47-8 1044709-50-3
 1044709-51-4 1044709-53-6 1044709-54-7
 1044709-58-1 1044709-59-2 1044709-61-6
 1044709-62-7 1044709-65-0 1044709-66-1
 1044709-68-3 1044709-69-4 1044709-72-9
 1044709-73-0


RL: PRPH (Prophetic)

(Preparation of substituted pyrazolo[4,3-d]pyrimidines as inhibitors of phosphodiesterase V)

RN 1044708-68-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
 1-(2-ethoxyethyl)-5-(1-piperazinyl)-3-(1-piperazinylmethyl)-N-4-
 pyrimidinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-69-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
N-cyclopentyl-1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-74-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-3-(4-
morpholinylmethyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-75-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1-piperazinyl)-N-4-pyrimidinyl-3-(1-pyrrolidinylmethyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-76-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[[(3R)-3-methyl-1-piperazinyl]methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-77-1 CAPLUS

CN	1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-N-phenyl-5-(1-piperazinyl)-3-(1-piperidinylmethyl)- (CA INDEX NAME)
----	--




RN 1044708-82-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-3-(4-morpholinylmethyl)-
N-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-83-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3S)-3-methyl-1-piperazinyl]-3-(1-piperidinylmethyl)-N-4-pyrimidinyl-1-
[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-84-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-3-(1-piperidinylmethyl)-
N-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-85-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-[(3S)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-
3-(1-piperidinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-90-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-3-(1-
piperidinylmethyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-91-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(4-fluorophenyl)-5-[(3R)-3-methyl-1-piperazinyl]-3-(1-piperidinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044708-92-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-3-(1-piperazinylmethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-93-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
N-cyclohexyl-1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044708-99-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-(1-piperazinyl)-3-(1-piperidinylmethyl)-N-4-
pyrimidinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-00-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)-3-(1-piperidinylmethyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-01-4 CAPLUS

CN 4-Piperidinol, 1-[[5-(1-piperazinyl)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-06-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-ethyl-N5-methyl-3-(4-morpholinylmethyl)-N7-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-07-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-ethyl-N7-(4-fluorophenyl)-N5-methyl-3-(4-morpholinylmethyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)



RN 1044709-08-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(2-methyl-1-piperidinyl)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-09-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(3,3-dimethyl-1-piperazinyl)methyl]-1-(2-ethoxyethyl)-5-(1-piperazinyl)-
N-4-pyrimidinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-14-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-[(3S)-3-methyl-1-piperazinyl]-3-(1-piperidinylmethyl)-
N-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-15-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-3-(1-
piperidinylmethyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-16-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-fluorophenyl)-5-[(3R)-3-methyl-1-piperazinyl]-3-(1-piperidinylmethyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




RN	1044709-17-2	CAPLUS
CN	1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-ethyl-N5-methyl-3-(1-piperazinylmethyl)-N7-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)	



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN	1044709-22-9	CAPLUS
CN	1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-[(hexahydro-1H-azepin-1-yl)methyl]-5-(1-piperazinyl)-N- 4-pyrimidinyl- (CA INDEX NAME)	


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-23-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(3,3-dimethyl-1-piperidinyl)methyl]-1-(2-ethoxyethyl)-5-(1-piperazinyl)-
N-4-pyrimidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-24-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-3-(1-piperidinylmethyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-25-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-ethyl-N5-methyl-3-(4-morpholinylmethyl)-N7-4-
pyrimidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-29-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
N-(1,1-dimethylethyl)-1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-
pyrimidinylamino)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-30-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
N-ethyl-N-methyl-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-31-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-N-(2,2,2-
trifluoroethyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-32-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-3-(4-morpholinylmethyl)-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-36-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(3,5-dimethyl-1-piperazinyl)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-
[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-37-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(4-fluorophenyl)-5-[(3R)-3-methyl-1-piperazinyl]-3-(4-
morpholinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306



RN 1044709-39-8 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,3-dimethyl-1-piperazinyl)-1-(2-ethoxyethyl)-3-(1-piperidinylmethyl)-N-
4-pyrimidinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-40-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3S)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-3-(1-
piperidinylmethyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-43-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-fluorophenyl)-5-(1-piperazinyl)-3-(1-piperidinylmethyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)



RN 1044709-44-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(2,6-dimethyl-1-piperidinyl)methyl]-1-(2-ethoxyethyl)-5-(1-piperazinyl)-
N-4-pyrimidinyl- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-46-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(4-fluorophenyl)-5-[(3S)-3-methyl-1-piperazinyl]-3-(1-piperidinylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044709-47-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-fluorophenyl)-5-(1-piperazinyl)-3-(1-piperazinylmethyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306



RN 1044709-50-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1-piperazinyl)-3-(1-piperidinylmethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-51-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
N-cyclopropyl-1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-
(CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-53-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-ethyl-N5-methyl-3-(1-piperidinylmethyl)-N7-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-54-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-(1-piperazinyl)-3-(1-piperidinylmethyl)-N-2-pyridinyl-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-58-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[[(3S)-3-methyl-1-piperazinyl]methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-59-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(1,1-dioxido-4-thiomorpholinyl)methyl]-1-(2-ethoxyethyl)-5-(1-
piperazinyl)-N-4-pyrimidinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-61-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-
3-(4-morpholinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-62-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,3-dimethyl-1-piperazinyl)-3-(1-piperidinylmethyl)-N-4-pyrimidinyl-1-
[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-65-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-3-(1-
piperidinylmethyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-66-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-
3-(1-piperidinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-68-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-fluorophenyl)-5-[(3S)-3-methyl-1-piperazinyl]-3-(1-piperidinylmethyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




RN 1044709-69-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(4-fluorophenyl)-5-(1-piperazinyl)-3-(1-
piperidinylmethyl)- (CA INDEX NAME)



RN 1044709-72-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3S)-3-methyl-1-piperazinyl]-3-(1-piperazinylmethyl)-N-4-pyrimidinyl-1-
[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 1044709-73-0 CAPLUS

CN Cyclohexanol, 4-[[[1-(2-ethoxyethyl)-5-(1-piperazinyl)-7-(4-pyrimidinylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 866922-33-0P 866922-37-4P 866922-39-6P
866922-41-0P 866922-43-2P 866922-45-4P
866922-48-7P 866922-49-8P 866922-51-2P
866922-52-3P 866922-53-4P 866922-56-7P
866922-59-0P 866922-62-5P 866922-66-9P
866922-70-5P 866922-73-8P 866922-76-1P
866922-81-8P 866922-84-1P 866922-87-4P
866922-89-6P 866922-91-0P 866922-93-2P
866922-94-3P 866922-95-4P 866922-96-5P
866922-97-6P 866922-98-7P 866922-99-8P
866923-00-4P 866923-01-5P 866923-02-6P
866923-03-7P 866923-04-8P 866923-05-9P
866923-06-0P 866923-07-1P 866923-08-2P
866923-09-3P 866923-11-7P 866923-13-9P
866923-15-1P 866923-17-3P 866923-19-5P
866923-21-9P 866923-23-1P 866923-25-3P
866923-27-5P 866923-29-7P


10580306

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrazolo[4,3-d]pyrimidines as inhibitors of phosphodiesterase V)

RN 866922-33-0 CAPLUS


CN Acetamide, 2-(dimethylamino)-N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-37-4 CAPLUS

CN Methanesulfonamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-39-6 CAPLUS

CN Methanesulfonamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-41-0 CAPLUS

CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-2-hydroxy- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-43-2 CAPLUS

CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-2-hydroxy- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-45-4 CAPLUS


CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-48-7 CAPLUS

CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-49-8 CAPLUS


CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-51-2 CAPLUS

CN Propanamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-52-3 CAPLUS

CN Propanamide, N-[[1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-53-4 CAPLUS


CN Propanamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-56-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[(methylamino)methyl]-N7-(4-methyl-2-pyridinyl)- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-59-0 CAPLUS


CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-N-methyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-62-5 CAPLUS

CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-N-methyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-66-9 CAPLUS

CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-N-methyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-70-5 CAPLUS

CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-(4-pyrimidinylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-N-methyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-73-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[(methylamino)methyl]-N7-2-pyrazinyl-, hydrochloride (1:?) (CA INDEX NAME)

10580306




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-76-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[(4-methyl-1-piperazinyl)methyl]-N7-(4-
methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-81-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]-N5,N5-
dimethyl-N7-(4-methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.

10580306




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-84-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]-N5,N5-
dimethyl-N7-(4-methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-87-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[[(3S)-3-methoxy-1-pyrrolidinyl]methyl]-N5,N5-dimethyl-
N7-(4-methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.

10580306




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-89-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[[(3R)-3-methoxy-1-pyrrolidinyl]methyl]-N5,N5-dimethyl-
N7-(4-methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-91-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[[(1-methylethyl)amino]methyl]-N7-(4-
methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)

10580306




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-93-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-3-
[(propylamino)methyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-94-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-3-(1-
pyrrolidinylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)

10580306




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-95-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[(ethylamino)methyl]-N5,N5-dimethyl-N7-(5-methyl-2-
pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-96-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(5-methyl-2-pyridinyl)-3-(4-
morpholinylmethyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-97-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-[(dimethylamino)methyl]-1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-
pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-98-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[[(2-methoxyethyl)amino]methyl]-N5,N5-dimethyl-N7-(4-
methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)

10580306




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-99-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-3-(4-
morpholinylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-00-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[(ethylamino)methyl]-N5,N5-dimethyl-N7-(4-methyl-2-
pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-01-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[(ethylamino)methyl]-N5,N5-dimethyl-N7-4-pyrimidinyl-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-02-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-[[(2-methoxyethyl) amino]methyl]-N5,N5-dimethyl-N7-4-
pyrimidinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-03-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-[(diethylamino)methyl]-1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-4-pyrimidinyl-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-04-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[(methylamino)methyl]-N7-4-pyrimidinyl-
, hydrochloride (1:?) (CA INDEX NAME)

10580306




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-05-9 CAPLUS

CN Ethanol, 2-[[1-(2-ethoxyethyl)-3-[(methylamino)methyl]-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-06-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5-(2-methoxyethyl)-N5-methyl-3-[(methylamino)methyl]-N7-(4-methyl-2-pyridinyl)-, hydrochloride (1:?) (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-07-1 CAPLUS

CN Ethanol, 2-[[1-(2-ethoxyethyl)-3-[(methylamino)methyl]-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, hydrochloride (1:?) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-08-2 CAPLUS

CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-N-propyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-09-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-3-(1-
piperazinylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-11-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1-piperazinyl)-3-(1-piperazinylmethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 866923-10-6

CMF C22 H30 F3 N11 O


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 866923-13-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-3-(4-morpholinylmethyl)-N-4-pyrimidinyl-1-
[2-(2,2,2-trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX
NAME)

CM 1

CRN 866923-12-8
CMF C23 H31 F3 N10 O2

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 866923-15-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(4-morpholinylmethyl)-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 866923-14-0

CMF C22 H29 F3 N10 O2


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 866923-17-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-ethyl-N5-methyl-N7-4-pyrimidinyl-3-(4-thiomorpholinylmethyl)-1-[2-
(2,2,2-trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (2:3) (CA INDEX
NAME)

CM 1

CRN 866923-16-2
CMF C21 H28 F3 N9 O S




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 866923-19-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-3-(1-piperidinylmethyl)-N-4-pyrimidinyl-1-
[2-(2,2,2-trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX
NAME)

CM 1

CRN 866923-18-4

CMF C24 H33 F3 N10 O

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2

10580306



RN 866923-21-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-3-(4-
thiomorpholinylmethyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 866923-20-8

CMF C23 H31 F3 N10 O S

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 866923-23-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R)-3-methyl-1-piperazinyl]-3-[(4-methyl-1-piperazinyl)methyl]-N-4-

10580306


pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate
(1:3) (CA INDEX NAME)

CM 1

CRN 866923-22-0

CMF C24 H34 F3 N11 O

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 866923-25-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-[(diethylamino)methyl]-N5,N5-diethyl-N7-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 866923-24-2

CMF C22 H32 F3 N9 O


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 866923-27-5 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-[(1,1-dioxido-4-thiomorpholinyl)methyl]-5-[(3R)-3-methyl-1-piperazinyl]-
N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-,
2,2,2-trifluoroacetate (2:5) (CA INDEX NAME)

CM 1

CRN 866923-26-4
CMF C23 H31 F3 N10 O3 S

Absolute stereochemistry.




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866923-29-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine,
5-(1-piperaziny1)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-N-(2,2,2-trifluoroethyl)-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

CM 1

CRN 866923-28-6

CMF C20 H24 F6 N10 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2




10580306

IT 792968-79-7P 866923-50-4P 866923-51-5P
866923-52-6P 866923-53-7P 866923-54-8P
866923-55-9P 866923-56-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of substituted pyrazolo[4,3-d]pyrimidines as inhibitors of
phosphodiesterase V)
RN 792968-79-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 866923-50-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 866923-51-5 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-(4-pyrimidinylamino)- (CA INDEX
NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-52-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxaldehyde,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-53-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxaldehyde,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-54-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxaldehyde,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-(4-pyrimidinylamino)- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-55-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-56-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]methyl]-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-,
1,1-dimethylethyl ester (CA INDEX NAME)

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10580306

L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:472160 CAPLUS

DOCUMENT NUMBER: 143:26628

TITLE: Preparation of pyrazolopyrimidines as cyclic guanylate
monophosphate-specific phosphodiesterase type 5
inhibitors

INVENTOR(S): Bell, Andrew; Brown, David; Bull, David; Fox, David;
Marsh, Ian; Morrell, Andrew; Palmer, Michael; Winslow,
Carol

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 147 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049617	A1	20050602	WO 2004-IB3791	20041119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2545196	A1	20050602	CA 2004-2545196	20041119
EP 1689752	A1	20060816	EP 2004-798915	20041119
EP 1689752	B1	20080227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR 2004016678	A	20070213	BR 2004-16678	20041119
JP 2007512317	T	20070517	JP 2006-540655	20041119
AT 387449	T	20080315	AT 2004-798915	20041119
ES 2300849	T3	20080616	ES 2004-798915	20041119
MX 2006PA05824	A	20060811	MX 2006-PA5824	20060523
US 20070105877	A1	20070510	US 2006-580306	20060926
PRIORITY APPLN. INFO.:			GB 2003-27323	A 20031124
			WO 2004-IB3791	W 20041119
OTHER SOURCE(S):		CASREACT 143:26628; MARPAT 143:26628		
GI				



AB The title compds. I [R1 = (un)substituted cycloalkyl, etc.; R2 = H, alkyl; R3, R4 = (un)substituted alkyl, alkenyl, etc.; R5 = YCONR15R16; Y = alkylenyl, etc.; R15, R16 = H, (un)substituted alkyl, etc.; R6, which may be attached at N1 or N2, is (un)substituted alkyl, alkenyl, etc.] are prepared. Thus, 1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-5-(pyrrolidin-1-yl)-3-(pyrrolidin-1-carbonyl)-1H-pyrazolo[4,3-d]pyrimidine was prepared from Me 5-chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate and pyrrolidine. Compds. of this invention in vitro showed IC50 values of 0.02 nM to 2.95 nM against cyclic guanylate monophosphate-specific phosphodiesterase type 5.


IT 852873-38-2P 852873-39-3P 852873-40-6P
 852873-41-7P 852873-42-8P 852873-43-9P
 852873-44-0P 852873-45-1P 852873-46-2P
 852873-47-3P 852873-48-4P 852873-49-5P
 852873-50-8P 852873-51-9P 852873-52-0P
 852873-53-1P 852873-54-2P 852873-55-3P
 852873-56-4P 852873-57-5P 852873-58-6P
 852873-59-7P 852873-60-0P 852873-61-1P
 852873-62-2P 852873-63-3P 852873-64-4P
 852873-65-5P 852873-66-6P 852873-67-7P
 852873-68-8P 852873-69-9P 852873-70-2P
 852873-71-3P 852873-72-4P 852873-73-5P
 852873-74-6P 852873-75-7P 852873-76-8P
 852873-77-9P 852873-78-0P 852873-79-1P
 852873-80-4P 852873-81-5P 852873-82-6P
 852873-83-7P 852873-84-8P 852873-85-9P
 852873-86-0P 852873-87-1P 852873-88-2P
 852873-89-3P 852873-90-6P 852873-91-7P
 852873-92-8P 852873-93-9P 852873-94-0P
 852873-96-2P 852873-97-3P 852873-98-4P
 852873-99-5P 852874-00-1P 852874-01-2P
 852874-02-3P 852874-03-4P 852874-04-5P
 852874-05-6P 852874-06-7P 852874-07-8P
 852874-08-9P 852874-09-0P 852874-10-3P
 852874-11-4P 852874-12-5P 852874-13-6P
 852874-14-7P 852874-15-8P 852874-16-9P
 852874-17-0P 852874-18-1P 852874-19-2P
 852874-20-5P 852874-21-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclic guanylate monophosphate-specific phosphodiesterase type 5 inhibitors)


10580306

RN 852873-38-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-(2-pyridinylamino)- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852873-39-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-methyl-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-(2-
propoxyethyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-40-6 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-41-7 CAPLUS

CN	Methanone, [1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-5-(1-pyrrolidinyl)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]-1-pyrrolidinyl- (CA INDEX NAME)
----	--




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-42-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(methylamino)-N-[2-(methylamino)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-43-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-
2-pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-44-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-4-
piperidinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-45-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-46-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-47-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylamino)-N-[2-(methylamino)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-48-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-49-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-4-
piperidinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-50-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-[(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-51-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-methyl-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-52-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-53-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-[2-(methylamino)ethyl]-7-[(4-methyl-
2-pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-54-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-7-[(4-
methyl-2-pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-55-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-4-
piperidinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-56-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-57-5 CAPLUS

CN Glycine, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-58-6 CAPLUS

CN L-Alanine, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-59-7 CAPLUS

CN D-Alanine, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-60-0 CAPLUS

CN β -Alanine, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-61-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-62-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-
methyl-2-pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-63-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-5-[methyl(1-methyl-4-piperidinyl)amino]-7-[(4-
methyl-2-pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-64-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N,1-dimethyl-7-[(4-methyl-2-pyridinyl)amino]-5-(1-piperazinyl)- (CA INDEX
NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-65-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N,N,1-trimethyl-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-66-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-7-[(4-methyl-2-pyridinyl)amino]-5-(1-
piperazinyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-67-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-68-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N,N-dimethyl-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-
methyl-2-pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-69-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-70-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N,1-dimethyl-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX
NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-71-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylamino)-1-methyl-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-72-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-methyl-5-[(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-4-
piperidinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-73-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-N,1-dimethyl-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-74-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-methyl-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-75-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-methyl-7-[(4-methyl-2-pyridinyl)amino]-N-[2-(1-
pyrrolidinyl)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-76-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-methyl-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-77-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-1-methyl-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-78-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-methyl-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-79-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-methyl-N-(1-methyl-4-piperidiny)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-80-4 CAPLUS

CN Methanone, [1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-
pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]-1-piperazinyl- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-81-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)-7-[(5-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-82-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)-7-(4-
pyrimidinylamino)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-83-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-[(5-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-84-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-(2-pyrazinylamino)- (CA INDEX
NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-85-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylamino)-N-(2-methoxyethyl)-7-[(5-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-86-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-87-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylamino)-N-methyl-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-88-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-[2-(methylamino)ethyl]-
(CA INDEX NAME)

10580306




RN 852873-89-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylamino)-N-[2-(methylamino)ethyl]- (CA INDEX NAME)



RN 852873-90-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylmethlamino)-N-[2-(methylamino)ethyl]- (CA INDEX NAME)



10580306


RN 852873-91-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-ethyl-5-(1-piperazinyl)- (CA
INDEX NAME)



RN 852873-92-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-N-(1-methylethyl)-5-[methyl(1-
methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-93-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-(2-methoxyethyl)-5-(methylamino)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-94-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-(1-methylethyl)-7-[(4-
methyl-2-pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-96-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-hydroxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-97-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-[2-(dimethylamino)ethyl]-5-(ethylamino)-1-(1-methylethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-98-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylamino)-N-(2-methoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-99-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-[(2-hydroxyethyl)methylamino]-N-methyl-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-00-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-[(2-methoxyethyl)amino]-N-methyl-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-01-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-[(2-methoxyethyl)methylamino]-N-methyl-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-02-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[(methylamino)carbonyl]-1-(2-
methylpropyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-
5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-03-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)- (CA INDEX NAME)




RN 852874-04-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-5-(ethylamino)- (CA INDEX NAME)


10580306



RN 852874-05-6 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-methyl- (CA
INDEX NAME)




RN 852874-06-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-methyl-5-[methyl(1-methyl-4-
piperidinyl)amino]- (CA INDEX NAME)




10580306

RN 852874-07-8 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-
methoxyethyl)- (CA INDEX NAME)




RN 852874-08-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclohexylamino)-1-(2-ethoxyethyl)-N-methyl-5-[3-(methylamino)-1-
azetidinyl]- (CA INDEX NAME)



RN 852874-09-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclohexylamino)-1-(2-ethoxyethyl)-N-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.

10580306



RN 852874-10-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclohexylamino)-1-(2-ethoxyethyl)-N-methyl-5-[methyl[(3S)-1-methyl-3-pyrrolidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852874-11-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-5-[methyl[(3S)-1-methyl-3-pyrrolidinyl]amino]-7-
[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-12-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-N-methyl-7-[(4-methyl-2-pyridinyl)amino]-5-[(3S)-1-
methyl-3-pyrrolidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-13-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-4-piperidinyl-
(CA INDEX NAME)

10580306




RN 852874-14-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylamino)-N-4-piperidinyl-
(CA INDEX NAME)



RN 852874-15-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-
(CA INDEX NAME)




RN 852874-16-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylamino)-


10580306

(CA INDEX NAME)



RN 852874-17-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]- (CA INDEX NAME)



RN 852874-18-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(2-aminoethyl)-7-(cyclopentylamino)-5-(diethylamino)-1-(2-ethoxyethyl)-
(CA INDEX NAME)

10580306




RN 852874-19-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-methyl-5-(1-piperazinyl)- (CA
INDEX NAME)



RN 852874-20-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)-5-(1-
piperazinyl)- (CA INDEX NAME)



10580306

RN 852874-21-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-methyl-1-(2-methylpropyl)-7-[(4-methyl-2-pyridinyl)amino]-5-(1-
piperazinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:472159 CAPLUS

DOCUMENT NUMBER: 143:26627

TITLE: Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines
with phosphodiesterase-5 (PDE5) inhibiting activity

INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Dack, Kevin
Neil; Fox, David Nathan Abraham; Marsh, Ian Roger;
Morrell, Andrew Ian; Palmer, Michael John; Winslow,
Carol Ann

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 282 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049616	A1	20050602	WO 2004-IB3747	20041112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004290643	A1	20050602	AU 2004-290643	20041112
AU 2004290643	B2	20080807		
CA 2546987	A1	20050602	CA 2004-2546987	20041112
EP 1689751	A1	20060816	EP 2004-798876	20041112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
CN 1882591	A	20061220	CN 2004-80034570	20041112
BR 2004016869	A	20070327	BR 2004-16869	20041112
JP 2007512314	T	20070517	JP 2006-540647	20041112
JP 4056015	B2	20080305		
SG 133614	A1	20070730	SG 2007-4860	20041112
NL 1027568	A1	20050526	NL 2004-1027568	20041123
NL 1027568	C2	20051130		
TW 265031	B	20061101	TW 2004-93136019	20041123
US 20050245544	A1	20051103	US 2004-997191	20041124
IN 2006DN02037	A	20070803	IN 2006-DN2037	20060413
MX 2006PA05914	A	20060627	MX 2006-PA5914	20060524
KR 2007026334	A	20070308	KR 2006-710152	20060524
KR 848216	B1	20080724		
NO 2006002950	A	20060823	NO 2006-2950	20060623
KR 2008052666	A	20080611	KR 2008-709034	20080415
PRIORITY APPLN. INFO.:			GB 2003-27319	A 20031124
			US 2004-535797P	P 20040112
			WO 2004-IB3747	W 20041112
			KR 2006-710152	A3 20060524

10580306

OTHER SOURCE(S): MARPAT 143:26627
GI



AB Title compds. [I; R1 = (substituted) cyclic group; R2 = H, alkyl; R3, R4 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R5 = YCO₂R₁₅, YR₁₆; R6 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, etc.; Y = bond, CH₂OCH₂, alkylene, cycloalkylene; R₁₅ = H, (substituted) alkyl; R₁₆ = tetrazolyl, trifluoromethyltriazolyl, methylsulfonyltriazolyl, etc.; dotted lines = double bonds to form an aromatic ring], were prepared. Thus, title compound (II) (preparation given) inhibited PDE-5 with IC₅₀ = 0.075 nM.

IT 853003-28-8P 853003-29-9P 853003-30-2P
853003-31-3P 853003-32-4P 853003-33-5P
853003-34-6P 853003-35-7P 853003-36-8P
853003-37-9P 853003-40-4P 853003-41-5P
853003-42-6P 853003-43-7P 853003-44-8P
853003-45-9P 853003-46-0P 853003-47-1P
853003-48-2P 853003-49-3P 853003-50-6P
853003-51-7P 853003-52-8P 853003-53-9P
853003-54-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(claimed compound; preparation of diaminopyrazolopyrimidines with phosphodiesterase-5 inhibiting activity)

RN 853003-28-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-((1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino])-methyl ester (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-29-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(6-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-30-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylanino)-7-[(4-methyl-2-pyridinyl)amino]-,
ethyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-31-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-,
2-(dimethylamino)ethyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-32-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(methylpropylamino)-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-33-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-1-(2-
propoxyethyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-34-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(4,6-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-35-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(cyclobutylmethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-36-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-37-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(2-methoxy-4-pyrimidinyl)amino]-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-40-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(4-fluoro-3-methylphenyl)amino]-5-[methyl(1-
methylethyl)amino]- (CA INDEX NAME)

10580306



RN 853003-41-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-
(CA INDEX NAME)



RN 853003-42-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(3,4-dimethylphenyl)amino]-1-(2-ethoxyethyl)-5-(ethylmethylamino)- (CA
INDEX NAME)

10580306



RN 853003-43-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(cyclopropylmethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-
methyl-2-pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-44-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(cyclopropylmethoxy)ethyl]-5-(ethylmethylanino)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-45-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-46-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(1-methylethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-47-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-48-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethylanino)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-49-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-50-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-[2-(3-fluoropropoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-51-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-52-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-1-[2-(2,2-difluoroethoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-53-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-[2-(2,2-difluoroethoxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-54-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-[2-(2,2-difluoroethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-
methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 853004-42-9P 853004-52-1P 853004-53-2P


853004-60-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of diaminopyrazolopyrimidines with phosphodiesterase-5 inhibiting activity)

RN 853004-42-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-
, methyl ester (CA INDEX NAME)



RN 853004-52-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-
, methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-53-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-60-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-fluoro-3-methylphenyl)amino]-,
methyl ester (CA INDEX NAME)



IT	853005-71-7P	853005-72-8P	853005-73-9P
	853005-74-0P	853005-75-1P	853005-76-2P
	853005-77-3P	853005-78-4P	853005-79-5P
	853005-80-8P	853005-81-9P	853005-82-0P
	853005-83-1P	853005-84-2P	853005-85-3P
	853005-86-4P	853005-87-5P	853005-88-6P
	853005-89-7P	853005-90-0P	853005-91-1P
	853005-92-2P	853005-93-3P	853005-94-4P
	853005-95-5P	853005-96-6P	853005-97-7P
	853005-98-8P	853005-99-9P	853006-00-5P
	853006-01-6P	853006-02-7P	853006-03-8P
	853006-04-9P	853006-05-0P	853006-06-1P
	853006-07-2P	853006-08-3P	853006-09-4P
	853006-10-7P	853006-11-8P	853006-12-9P
	853006-13-0P	853006-14-1P	853006-15-2P
	853006-16-3P	853006-17-4P	853006-18-5P
	853006-19-6P	853006-20-9P	853006-22-1P
	853006-23-2P	853006-24-3P	853006-25-4P
	853006-26-5P	853006-27-6P	853006-28-7P
	853006-29-8P	853006-30-1P	853006-31-2P
	853006-32-3P	853006-33-4P	853006-38-9P
	853006-39-0P	853006-40-3P	853006-41-4P
	853006-42-5P	853006-43-6P	853006-44-7P
	853006-45-8P	853006-46-9P	853006-47-0P
	853006-48-1P	853006-49-2P	853006-50-5P
	853006-51-6P	853006-52-7P	853006-53-8P
	853006-54-9P	853006-55-0P	853006-56-1P
	853006-57-2P	853006-58-3P	853006-59-4P
	853006-60-7P	853006-61-8P	853006-62-9P
	853006-64-1P	853006-65-2P	853006-66-3P
	853006-67-4P	853006-68-5P	853006-69-6P
	853006-70-9P	853006-71-0P	853006-72-1P
	853006-73-2P	853006-74-3P	853006-75-4P
	853006-76-5P	853006-78-7P	853006-79-8P
	853006-82-3P	853006-83-4P	853006-87-8P
	853006-90-3P	853006-93-6P	853006-96-9P
	853006-99-2P	853007-01-9P	853007-04-2P
	853007-06-4P	853007-08-6P	853007-11-1P

10580306

853007-13-3P 853007-16-6P 853007-18-8P
853007-20-2P 853007-22-4P 853007-24-6P
853007-25-7P 853007-26-8P 853007-27-9P
853007-28-0P 853007-29-1P 853007-30-4P
853007-31-5P 853007-32-6P 853007-33-7P
853007-34-8P 853007-35-9P 853007-36-0P
853007-37-1P 853007-38-2P 853007-39-3P
853007-40-6P 853007-41-7P 853007-42-8P
853007-43-9P 853007-44-0P 853007-45-1P
853007-46-2P 853007-47-3P 853007-49-5P
853007-50-8P 853007-51-9P 853007-52-0P
853007-53-1P 853007-54-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of diaminopyrazolopyrimidines with phosphodiesterase-5
inhibiting activity)

RN 853005-71-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-72-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-,
methyl ester (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-73-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-
pyridinyl)amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-74-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-, ethyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-75-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-76-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[(3S)-3-methoxy-1-pyrrolidinyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-77-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[(3R)-3-methoxy-1-pyrrolidinyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-78-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-79-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(2-methylpropyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-80-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[(2-methoxyethyl)methylamino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-81-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(cyclopentylmethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-82-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-(2-propoxyethyl)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-83-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(4-methyl-2-pyridinyl)amino]-1-(2-propoxyethyl)-5-(1-pyrrolidinyl)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-84-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-methoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-85-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-86-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-87-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(5-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-88-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-7-[(4,6-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-89-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-(4-pyrimidinylamino)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-90-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-(2-pyrazinylamino)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853005-91-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-(methylpropylamino)- (CA INDEX
NAME)



RN 853005-92-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-
(CA INDEX NAME)



10580306


RN 853005-93-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclobutylamino)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]- (CA
INDEX NAME)




RN 853005-94-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclobutylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)- (CA INDEX NAME)




RN 853005-95-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclopropylamino)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-
(CA INDEX NAME)




10580306

RN 853005-96-6 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclopropylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)- (CA INDEX NAME)




RN 853005-97-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(4-ethyl-2-pyridinyl)amino]-5-[methyl(1-methylethyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-98-8 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-ethyl-2-pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-99-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(6-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-00-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(6-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-01-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(4,5-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)-5-(ethylmethlamino)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-02-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-7-[(4,5-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853006-03-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclohexylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)- (CA INDEX NAME)



RN 853006-04-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-(ethylmethylamino)- (CA INDEX NAME)



10580306


RN 853006-05-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 853006-06-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-(ethylamino)- (CA INDEX NAME)




RN 853006-07-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]- (CA INDEX NAME)


10580306



RN 853006-08-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclohexylamino)-5-(diethylamino)-1-(2-ethoxyethyl)- (CA INDEX NAME)




RN 853006-09-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-(methanediylamino)- (CA INDEX NAME)



RN 853006-10-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-[(cyclopropylmethyl)propylamino]-1-(2-ethoxyethyl)-7-[(4-methyl-2-

10580306


pyridinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-11-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylpropyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-12-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[ethyl(2-methoxyethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-13-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-5-(2-methyl-1-
pyrrolidinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-14-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[[(1S)-1-methylpropyl]amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-15-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[[[(1R)-1-methylpropyl]amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-16-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-pyran-
4-yl)methyl]- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-17-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-
pyran-4-yl)methyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-18-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-pyran-
2-yl)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-19-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-
pyran-2-yl)methyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-20-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-[2-(1-methylethoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-22-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-1-[2-(1-methylethoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-23-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylamino)-1-[2-(1-methylethoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-24-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-[(2R)-2-methoxypropyl]-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-25-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-1-[(2R)-2-methoxypropyl]-7-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-26-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-1-[(2R)-2-methoxypropyl]-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)

Absolute stereochemistry.




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-27-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[[(3R)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853006-28-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-1-(2-ethoxyethyl)-7-[[(3R)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853006-29-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(cyclobutylmethylamino)-1-(2-ethoxyethyl)-7-[[(3R)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.

10580306



RN 853006-30-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(2-methoxy-4-pyrimidinyl)amino]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-31-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(2-methyl-4-
pyrimidinyl)amino]- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-32-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(2-methyl-4-pyrimidinyl)amino]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-33-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(2,6-dimethyl-4-pyrimidinyl)amino]-1-(2-ethoxyethyl)-5-
(ethylmethylamino)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-38-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(5-fluoro-2-pyridinyl)amino]-5-[methyl(1-
methylethyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-39-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(tetrahydro-2H-pyran-4-yl)amino]-
(CA INDEX NAME)



RN 853006-40-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

10580306



RN 853006-41-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(6-methoxy-2-pyridinyl)amino]-5-[methyl(1-methylethyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-42-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-fluoro-3-methylphenyl)amino]-
(CA INDEX NAME)

10580306



RN 853006-43-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(3-fluorophenyl)amino]-5-[methyl(1-methylethyl)amino]-
(CA INDEX NAME)



RN 853006-44-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(2,4-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]- (CA INDEX NAME)

10580306



RN 853006-45-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(3,4-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]- (CA INDEX NAME)



RN 853006-46-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(3,5-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]- (CA INDEX NAME)

10580306




RN 853006-47-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(2,5-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]- (CA INDEX NAME)



RN 853006-48-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(2,3-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]- (CA INDEX NAME)



10580306


RN 853006-49-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(3-methylphenyl)amino]-
(CA INDEX NAME)



RN 853006-50-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-(phenylamino)- (CA
INDEX NAME)



RN 853006-51-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylanino)-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-52-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(6-ethyl-2-pyridinyl)amino]-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-53-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(6-ethyl-2-pyridinyl)amino]- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-54-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(6-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-55-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(2-fluoro-5-methylphenyl)amino]-
(CA INDEX NAME)

10580306



RN 853006-56-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethlamino)-7-[(2-fluoro-5-methylphenyl)amino]-
(CA INDEX NAME)



RN 853006-57-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-7-[(3,4-dimethylphenyl)amino]-1-(2-ethoxyethyl)- (CA
INDEX NAME)

10580306



RN 853006-58-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(2-fluorophenyl)amino]-5-[methyl(1-methylethyl)amino]-
(CA INDEX NAME)



RN 853006-59-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-(2-pyridinylamino)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-60-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(2-methoxyethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-61-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(3-methoxybutyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-62-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[(2R)-2-methoxypropyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-64-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-65-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxymethyl)-5-(ethylmethylamino)-7-[(3-methylphenyl)amino]- (CA
INDEX NAME)



RN 853006-66-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-67-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(6-methyl-4-pyrimidinyl)amino]-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-68-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[[4-(hydroxymethyl)-2-
pyridinyl]amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-69-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(cyclobutylloxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-70-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(6-methyl-4-
pyrimidinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-71-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(cyclobutyloxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-72-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-7-[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)amino]-1-(2-
ethoxyethyl)- (CA INDEX NAME)

10580306



RN 853006-73-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-74-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-75-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-76-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(4-methyl-2-pyridinyl)amino]-5-(2-methyl-1-pyrrolidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-78-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(cyclobutylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-79-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-1-(2-propoxyethyl)-7-(2-pyridinylamino)- (CA INDEX
NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-82-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-[methyl(1-methylethyl)amino]-1-(2-propoxyethyl)-7-(2-pyridinylamino)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-83-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-1-(2-propoxyethyl)-7-(2-pyridinylamino)- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-87-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-5-(1-pyrrolidinyl)- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-90-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[(2S)-2-methoxypropyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-93-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-7-[(3-methylphenyl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306



RN 853006-96-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




RN 853006-99-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-[methyl(1-methylethyl)amino]-7-[(3-methylphenyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




RN 853007-01-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(4-fluoro-3-methylphenyl)amino]-5-[methyl(1-methylethyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)



RN 853007-04-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-trifluoropropoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-06-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-
trifluoropropoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-08-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-
trifluoropropoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-11-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-13-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(3-fluoropropoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-16-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-18-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-20-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethanamine)-7-[(3-methylphenyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)



RN 853007-22-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethanamine)-7-[(6-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-24-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(methylpropylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-25-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-26-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-[(2-methoxyethyl)methylamino]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-27-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[[4-(hydroxymethyl)-2-
pyridinyl]amino]-N-(methylsulfonyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-28-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(dimethylamino)-1-(2-ethoxyethyl)-N-(ethylsulfonyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-29-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethlamino)-N-(ethylsulfonyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-30-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-1-(2-ethoxyethyl)-N-(ethylsulfonyl)-7-[(4-methyl-2-
pyridinyl)amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-31-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-(2-ethoxyethyl)-5-(ethylmethlamino)-7-[(6-methyl-4-pyrimidinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-32-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-1-(2-ethoxyethyl)-7-[(6-methyl-4-pyrimidinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853007-33-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-N-(methylsulfonyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




RN 853007-34-8 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-N-(methanesulfonyl)-1-
[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




RN 853007-35-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-7-[(3-methylphenyl)amino]-N-(methanesulfonyl)-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306



RN 853007-36-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-37-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-[2-(cyclobutyloxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-
pyridinyl)amino]-N-(methylsulfonyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-38-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
1-[2-(cyclobutyl)oxyethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-N-(methanesulfonyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-39-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-N-(methanesulfonyl)-1-(2-propoxyethyl)-7-(2-
pyridinylamino)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-40-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-N-(ethylsulfonyl)-1-(2-propoxyethyl)-7-(2-
pyridinylamino)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-41-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-[methyl(1-methylethyl)amino]-N-(methylsulfonyl)-1-(2-propoxyethyl)-7-(2-
pyridinylamino)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-42-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
N-(ethylsulfonyl)-5-[methyl(1-methylethyl)amino]-1-(2-propoxyethyl)-7-(2-
pyridinylamino)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-43-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-N-(methylsulfonyl)-1-(2-propoxyethyl)-7-(2-
pyridinylamino)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-44-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-N-(ethylsulfonyl)-1-(2-propoxyethyl)-7-(2-pyridinylamino)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-45-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethlamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-
(2-propoxyethyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-46-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-
[2-(3,3,3-trifluoropropoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-47-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)-1-[2-(3,3,3-trifluoropropoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-49-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methanesulfonyl)-1-[2-(3,3,3-trifluoropropoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-50-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethanlamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methanesulfonyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-51-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-52-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-(2-
propoxyethyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-53-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)-1-(2-propoxyethyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-54-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide,
5-(ethylmethylanino)-1-(2-hydroxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-
(methylsulfonyl)- (CA INDEX NAME)

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 853004-35-0P 853004-36-1P 853004-38-3P
853004-39-4P 853004-40-7P 853004-41-8P
853004-43-0P 853004-44-1P 853004-45-2P
853004-46-3P 853004-47-4P 853004-48-5P
853004-49-6P 853004-50-9P 853004-51-0P
853004-54-3P 853004-55-4P 853004-56-5P
853004-57-6P 853004-58-7P 853004-59-8P
853004-61-2P 853004-62-3P 853004-63-4P
853004-64-5P 853004-65-6P 853004-66-7P
853005-51-3P 853005-52-4P 853005-53-5P
853005-54-6P 853005-55-7P 853005-56-8P
853005-57-9P 853005-58-0P 853005-59-1P
853005-60-4P 853005-61-5P 853005-62-6P
853005-63-7P 853005-64-8P 853005-65-9P
853005-66-0P 853005-67-1P 853005-68-2P
853005-69-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of diaminopyrazolopyrimidines with phosphodiesterase-5
inhibiting activity)

RN 853004-35-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(cyclopropylmethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-
methyl-2-pyridinyl)amino]-, methyl ester (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-36-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[(2R)-2-methoxypropyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-38-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(1-methylethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-39-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(3-methoxybutyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-40-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(5-fluoro-2-pyridinyl)amino]-5-[methyl(1-
methylethyl)amino]-, methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-41-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(4-fluoro-3-methylphenyl)amino]-5-[methyl(1-methylethyl)amino]-, methyl ester (CA INDEX NAME)



RN 853004-43-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(6-methoxy-2-pyridinyl)amino]-5-[methyl(1-methylethyl)amino]-, methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853004-44-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-(phenylamino)-, methyl
ester (CA INDEX NAME)



RN 853004-45-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(3-methylphenyl)amino]-
, methyl ester (CA INDEX NAME)



10580306


RN 853004-46-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(3-fluorophenyl)amino]-5-[methyl(1-methylethyl)amino]-
, methyl ester (CA INDEX NAME)



RN 853004-47-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(2,4-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]-, methyl ester (CA INDEX NAME)



RN 853004-48-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(tetrahydro-2H-pyran-4-
yl)amino]-, methyl ester (CA INDEX NAME)

10580306



RN 853004-49-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(tetrahydro-2H-pyran-4-yl)amino]-,
methyl ester (CA INDEX NAME)



RN 853004-50-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(2-methoxyethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-51-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(6-ethyl-2-pyridinyl)amino]-,
methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-54-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethyamino)-7-[(6-ethyl-4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-55-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-(2-pyridinylamino)-,
methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-56-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(3,4-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]-, methyl ester (CA INDEX NAME)

10580306



RN 853004-57-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(3,5-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]-, methyl ester (CA INDEX NAME)



RN 853004-58-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(2,5-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]-, methyl ester (CA INDEX NAME)

10580306



RN 853004-59-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(2,3-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-
methylethyl)amino]-, methyl ester (CA INDEX NAME)



RN 853004-61-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(2-fluoro-5-methylphenyl)amino]-,
methyl ester (CA INDEX NAME)

10580306



RN 853004-62-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-5-(ethylmethlamino)-7-[(2-fluoro-5-methylphenyl)amino]-
, methyl ester (CA INDEX NAME)



RN 853004-63-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(dimethylamino)-7-[(3,4-dimethylphenyl)amino]-1-(2-ethoxyethyl)-, methyl
ester (CA INDEX NAME)

10580306



RN 853004-64-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(3,4-dimethylphenyl)amino]-1-(2-ethoxyethyl)-5-(ethylmethyamino)-,
methyl ester (CA INDEX NAME)



RN 853004-65-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(2-fluorophenyl)amino]-5-[methyl(1-methylethyl)amino]-,
methyl ester (CA INDEX NAME)

10580306



RN 853004-66-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(cyclopropylmethoxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-51-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-1-(2-propoxyethyl)-7-(2-pyridinylamino)-, methyl
ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-52-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-1-(2-propoxyethyl)-7-(2-pyridinylamino)-, methyl ester
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-53-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-[methyl(1-methylethyl)amino]-1-(2-propoxyethyl)-7-(2-pyridinylamino)-,
methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-54-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-7-[(3-methylphenyl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, methyl ester (CA INDEX NAME)



RN 853005-55-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, methyl ester (CA INDEX NAME)

10580306



RN 853005-56-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-[methyl(1-methylethyl)amino]-7-[(3-methylphenyl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, methyl ester (CA INDEX NAME)



RN 853005-57-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-1-[2-(2,2,2-
trifluoroethoxy)ethyl]-, methyl ester (CA INDEX NAME)

10580306



RN 853005-58-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
7-[(4-fluoro-3-methylphenyl)amino]-5-[methyl(1-methylethyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, methyl ester (CA INDEX NAME)



RN 853005-59-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(2,2-difluoroethoxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-60-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-1-[2-(2,2-difluoroethoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-61-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(2,2-difluoroethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-
methyl-2-pyridinyl)amino]-, methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-62-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-
trifluoropropoxy)ethyl]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-63-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-
trifluoropropoxy)ethyl]-, methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-64-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-
trifluoropropoxy)ethyl]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-65-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(ethylmethylanino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-66-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[2-(3-fluoropropoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-67-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
5-(diethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-68-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-5-(1-pyrrolidinyl)-,
methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-69-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid,
1-[(2S)-2-methoxypropyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-
pyridinyl)amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:965255 CAPLUS

DOCUMENT NUMBER: 141:410950

TITLE: Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in the treatment of hypertension

INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Fox, David Nathan Abraham; Marsh, Ian Roger; Morrell, Andrew Ian; Palmer, Michael John; Winslow, Carol Ann

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 279 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096810	A1	20041111	WO 2004-IB1433	20040422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004234158	A1	20041111	AU 2004-234158	20040422
CA 2523831	A1	20041111	CA 2004-2523831	20040422
CA 2523831	C	20081118		
EP 1620437	A1	20060201	EP 2004-728868	20040422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009903	A	20060425	BR 2004-9903	20040422
CN 1780841	A	20060531	CN 2004-80011467	20040422
JP 2006524636	T	20061102	JP 2006-500346	20040422
JP 4015176	B2	20071128		
NL 1026074	A1	20041101	NL 2004-1026074	20040428
NL 1026074	C2	20050809		
TW 273908	B	20070221	TW 2004-93111926	20040428
US 20050043325	A1	20050224	US 2004-834484	20040429
US 7262192	B2	20070828		
IN 2005DN03964	A	20070831	IN 2005-DN3964	20050905
NO 2005004404	A	20051124	NO 2005-4404	20050922
MX 2005PA11643	A	20051215	MX 2005-PA11643	20051028
KR 824193	B1	20080421	KR 2005-720497	20051028
JP 2007217419	A	20070830	JP 2007-67736	20070316
US 20070270412	A1	20071122	US 2007-831021	20070731
PRIORITY APPLN. INFO.:			GB 2003-9780	A 20030429
			GB 2003-27748	A 20031128
			US 2003-476678P	P 20030606
			US 2004-538147P	P 20040120
			JP 2006-500346	A3 20040422

WO 2004-IB1433 A 20040422
US 2004-834484 A1 20040429

OTHER SOURCE(S): MARPAT 141:410950
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein R1 = (un)substituted cycloalkyl, cycloalkenyl, (un)substituted pyridin-2-yl, (un)fused Ph, etc.; R2 = H, alkyl; R3, R4 = independently (un)substituted alkyl, alkenyl, cycloalkyl, etc.; or NR3R4 = piperazin-1-yl, monocyclic, saturated polycyclic; R5 = (un)substituted halo/alkyl, alkenyl, alkynyl, cycloalkyl; R6 = H, (un)substituted alkyl, haloalkyl, alkenyl, alkynyl, etc.] were prepared as selective PDE5 inhibitors. For example, II•2HCl was prepared from (4-Methylpyridin-2-yl)amine, dichloride III (general preparation given), and tert-Bu piperazine-1-carboxylate. I gave IC50 values < 10,000 nM in an in vitro assay for PDE5 inhibition. Thus, I are used for treating hypertension.

IT 792966-67-7P 792966-68-8P 792966-69-9P
792966-70-2P 792966-71-3P 792966-72-4P
792966-73-5P 792966-74-6P 792966-75-7P
792966-76-8P 792966-77-9P,
1-(2-Ethoxyethyl)-3-methyl-5-((3R)-3-methylpiperazin-1-yl)-N-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792966-78-0P
792966-79-1P 792966-80-4P 792966-81-5P,
1-(2-Ethoxyethyl)-3-ethyl-5-((3R)-3-methylpiperazin-1-yl)-N-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792966-82-6P
792966-83-7P 792966-84-8P 792966-85-9P
792966-86-0P 792966-88-2P 792966-89-3P,
1-(2-Isopropoxyethyl)-3-methyl-5-((3R)-3-methylpiperazin-1-yl)-N-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792966-90-6P
792966-91-7P 792966-92-8P 792966-93-9P
792966-94-0P 792966-95-1P 792966-96-2P
792966-97-3P 792966-98-4P 792966-99-5P
792967-00-1P 792967-01-2P 792967-02-3P
792967-03-4P 792967-04-5P 792967-05-6P
792967-06-7P 792967-07-8P 792967-09-0P
792967-11-4P 792967-13-6P 792967-15-8P
792967-17-0P 792967-19-2P 792967-21-6P
792967-23-8P 792967-25-0P 792967-27-2P
792967-29-4P 792967-31-8P 792967-33-0P
792967-35-2P 792967-37-4P 792967-39-6P
792967-41-0P 792967-43-2P 792967-45-4P
792967-47-6P 792967-49-8P 792967-51-2P
792967-53-4P 792967-54-5P 792967-56-7P
792967-57-8P 792967-59-0P 792967-60-3P
792967-61-4P 792967-62-5P 792967-64-7P
792967-66-9P 792967-68-1P 792967-70-5P
792967-72-7P 792967-73-8P 792967-74-9P
792967-75-0P 792967-76-1P 792967-77-2P
792967-78-3P 792967-79-4P 792967-80-7P
792967-81-8P 792967-82-9P 792967-83-0P
792967-84-1P 792967-85-2P 792967-86-3P
792967-87-4P, 1-Methyl-5-((3R)-3-methylpiperazin-1-yl)-3-propyl-N-

pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792967-88-5P
 792967-89-6P 792967-90-9P 792967-91-0P
 792967-92-1P 792967-93-2P 792967-94-3P
 792967-95-4P 792967-96-5P 792967-97-6P
 792967-98-7P 792967-99-8P 792968-00-4P
 792968-01-5P 792968-02-6P 792968-03-7P
 792968-04-8P 792968-05-9P 792968-06-0P
 792968-07-1P 792968-08-2P 792968-09-3P
 792968-10-6P 792968-11-7P 792968-12-8P
 792968-13-9P 792968-14-0P 792968-15-1P
 792968-16-2P 792968-17-3P 792968-18-4P
 792968-19-5P 792968-20-8P 792968-21-9P
 792968-22-0P 792968-23-1P 792968-24-2P
 792968-25-3P 792968-26-4P 792968-27-5P
 792968-28-6P 792968-29-7P 792968-30-0P
 792968-31-1P 792968-32-2P 792968-33-3P
 792968-34-4P, 5-((2R,5S)-2,5-Dimethylpiperazin-1-yl)-1-(2-ethoxyethyl)-3-methyl-N-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792968-35-5P 792968-36-6P 792968-37-7P
 , 5-((2R,5S)-2,5-Dimethylpiperazin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792968-38-8P
 792968-39-9P 792968-40-2P 792968-41-3P
 792968-42-4P 792968-43-5P 792968-44-6P
 792968-45-7P 792968-46-8P 792968-47-9P
 792968-48-0P 792968-49-1P,
 3-Ethyl-1-(2-methoxyethyl)-N'-(4-methylpyridin-2-yl)-N-[2-(pyrazol-1-yl)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-50-4P,
 (2S)-2-[[3-Ethyl-1-(2-methoxyethyl)-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]propan-1-ol 792968-51-5P
 792968-52-6P 792968-53-7P 792968-54-8P
 792968-55-9P 792968-56-0P 792968-57-1P,
 1-(2-Ethoxyethyl)-N-methyl-3-methyl-N'-(4-methylpyridin-2-yl)-N-((3S)-1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-58-2P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N'-(4-methylpyridin-2-yl)-N-((3S)-1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-59-3P,
 N-[3-Methyl-5-(piperazin-1-yl)-1-[(tetrahydropyran-2-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-5-methylpyridin-2-ylamine dihydrochloride 792968-60-6P 792968-61-7P 792968-62-8P
 792968-63-9P 792968-64-0P 792968-65-1P
 792968-66-2P 792968-75-3P,
 N-[3-Isopropyl-1-(2-methoxyethyl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine bis(trifluoroacetate) 792968-76-4P, N-[3-Isopropyl-1-(2-methoxyethyl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-5-methylpyridin-2-ylamine 792968-77-5P, N-[3-Ethyl-1-(2-methoxyethyl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-5-methyl-2H-pyrazol-3-ylamine 792968-78-6P, [1-(2-Ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol 792968-79-7P, [5-Dimethylamino-1-(2-ethoxyethyl)-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol 792968-80-0P, N-[1-(2-Ethoxyethyl)-3-(methoxymethyl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine dihydrochloride 792968-81-1P 792968-82-2P,
 1-(2-Ethoxyethyl)-3-(methoxymethyl)-N,N-dimethyl-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-83-3P,
 N-[1-(2-Ethoxyethyl)-3-(ethoxymethyl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-

d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine dihydrochloride
 792968-84-4P 792968-85-5P,
 1-(2-Ethoxyethyl)-3-(ethoxymethyl)-N,N-dimethyl-N'-(4-methylpyridin-2-yl)-
 1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-86-6P
 792968-87-7P, N-[1-(2-Ethoxyethyl)-3-(methoxymethyl)-5-(piperazin-
 1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]pyrimidin-4-ylamine dihydrochloride
 792968-88-8P, 1-(2-Ethoxyethyl)-N-methyl-3-methyl-N-((3S)-1-
 methylpyrrolidin-3-yl)-N'-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidine-5,7-
 diamine 792968-89-9P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N'-(5-
 methylpyridin-2-yl)-N-((3S)-1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-
 d]pyrimidine-5,7-diamine 792968-90-2P,
 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N-((3S)-1-methylpyrrolidin-3-yl)-N'-
 pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 792968-91-3P 792968-92-4P 792968-93-5P
 792968-94-6P 792968-95-7P 792968-96-8P
 792968-97-9P 792968-98-0P 792968-99-1P
 792969-01-8P 792969-03-0P 792969-04-1P
 792969-05-2P 792969-06-3P 792969-07-4P
 792969-08-5P 792969-09-6P,
 N-[1-(2-Ethoxyethyl)-3-methoxymethyl-5-((3R)-3-methylpiperazin-1-yl)-1H-
 pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-ylamine
 792969-10-9P 792969-11-0P 792969-12-1P
 792969-13-2P 792969-14-3P 792969-15-4P
 792969-16-5P 792969-17-6P 792969-18-7P
 792969-19-8P 792969-20-1P 792969-21-2P
 792969-22-3P, N-[3-Methyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-
 (2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]pyrimidin-4-
 ylamine 792969-23-4P 792969-24-5P 792969-25-6P
 792969-26-7P 792969-27-8P,
 N-[5-[(1S,4S)-2,5-Diazabicyclo[2.2.1]hept-2-yl]-1-(2-ethoxyethyl)-3-ethyl-
 1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine
 monohydrochloride 792969-28-9P,
 N-[5-[(1S,4S)-2,5-Diazabicyclo[2.2.1]hept-2-yl]-3-methoxymethyl-1-(2-
 propoxyethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine
 792969-29-0P 792969-30-3P,
 N-[5-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-1-(2-ethoxyethyl)-3-methyl-1H-
 pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine
 792969-31-4P 792969-32-5P 792969-33-6P
 792969-34-7P 792969-35-8P 792969-36-9P,
 N-[5-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-3-methyl-1-[2-(2,2,2-
 trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-
 ylamine 792969-37-0P,
 N-[5-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-3-methyl-1-(2-propoxyethyl)-1H-
 pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-ylamine
 792969-38-1P 792969-39-2P 792969-40-5P
 792969-41-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (PDE5 inhibitor; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as
 selective PDE5 inhibitors useful in treatment of hypertension)
 RN 792966-67-7 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
 3-ethyl-1-(2-methoxyethyl)-N5-methyl-N7-(4-methyl-2-pyridinyl)- (CA INDEX
 NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-68-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-4-
pyrimidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-69-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3-amino-1-azetidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-4-pyrimidinyl- (CA
INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-70-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-1-(2-
propoxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-71-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-methoxyethyl)-3-(1-methylethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-72-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)- (CA
INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-73-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(5-methyl-2-pyridinyl)-1-(2-propoxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-74-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-methoxyethyl)-3-(1-methylethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(5-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-75-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-1-(1-methylethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(5-methyl-2-
pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-76-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(3-methoxypropyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-77-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-78-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-79-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-(1-methylethyl)-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-80-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3S)-3-(1-methylethyl)-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-81-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-82-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-83-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-(1-methylethyl)-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-84-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3S)-3-(1-methylethyl)-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-85-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-ethyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-86-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-1-[2-(1-methylethoxy)ethyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.

10580306




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-88-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-4-
pyrimidinyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-89-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-1-[2-(1-methylethoxy)ethyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-90-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-1-(1-methylethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-91-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(3-ethoxypropyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.

10580306




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-92-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-4-pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-93-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[(3R)-3-methyl-1-piperazinyl]-3-propyl-N-3-pyridazinyl- (CA
INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-94-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-ethyl-N-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 792966-95-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(2,5-dimethyl-1-piperazinyl)-1-methyl-N-(5-methyl-2-pyridinyl)-3-propyl-
, hydrochloride (1:?) (CA INDEX NAME)

10580306




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-96-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(2-methyl-1-piperazinyl)-N-(5-methyl-2-pyridinyl)-3-propyl-,
hydrochloride (1:?) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-97-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(3-methyl-1-piperazinyl)-N-(5-methyl-2-pyridinyl)-3-propyl-,
hydrochloride (1:?) (CA INDEX NAME)

10580306




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-98-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,5-dimethyl-1-piperazinyl)-1-methyl-N-(5-methyl-2-pyridinyl)-3-propyl-
, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-99-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(2,6-dimethyl-1-piperazinyl)-1-methyl-N-(5-methyl-2-pyridinyl)-3-propyl-
, hydrochloride (1:?) (CA INDEX NAME)

10580306




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-00-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)-3-propyl-,
hydrochloride (1:?) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-01-2 CAPLUS

CN 4-Piperidinol, 1-[1-methyl-7-[(5-methyl-2-pyridinyl)amino]-3-propyl-1H-
pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-02-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-N-(5-methyl-2-pyridinyl)-5-(1-piperidinyl)-3-propyl- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-03-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-3-azetidiny-1-methyl-N7-(5-methyl-2-pyridinyl)-3-propyl- (CA INDEX
NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-04-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-3-azetidinyln-5,1-dimethyl-N7-(5-methyl-2-pyridinyl)-3-propyl- (CA
INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-05-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[(3S)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-3-propyl-
(CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-06-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-3-propyl-
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-07-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(4-methyl-1-piperazinyl)-N-(4-methyl-2-pyridinyl)-3-propyl-
(CA INDEX NAME)

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792967-09-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N5-(1-methyl-4-piperidinyl)-N7-(4-methyl-2-pyridinyl)-3-propyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-08-9

CMF C21 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 792967-11-4 CAPLUS


10580306

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,1-dimethyl-N5-(1-methyl-4-piperidiny1)-N7-(4-methyl-2-pyridinyl)-3-
propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-10-3

CMF C22 H32 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 792967-13-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-(1-methyl-3-pyrrolidinyl)-3-
propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-12-5

CMF C21 H30 N8

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-15-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(4-amino-1-piperidinyl)-1-methyl-N-(4-methyl-2-pyridinyl)-3-propyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-14-7

CMF C20 H28 N8




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-17-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(hexahydro-1H-1,4-diazepin-1-yl)-1-methyl-N-(4-methyl-2-pyridinyl)-3-
propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-16-9

CMF C20 H28 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




10580306

RN 792967-19-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-methyl-N-(4-methyl-2-
pyridinyl)-3-propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-18-1

CMF C21 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-21-6 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N7-(4-methyl-2-pyridinyl)-N5-4-piperidinyl-3-propyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-20-5

CMF C20 H28 N8

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-23-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[3-(aminomethyl)-1-piperidinyl]-1-methyl-N-(4-methyl-2-pyridinyl)-3-
propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-22-7

CMF C21 H30 N8




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-25-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N5-[2-(methylamino)ethyl]-N7-(4-methyl-2-pyridinyl)-3-propyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-24-9

CMF C18 H26 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 792967-27-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,


10580306

N5-(3-aminopropyl)-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-26-1

CMF C18 H26 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 792967-29-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[4-(dimethylamino)-1-piperidinyl]-1-methyl-N-(4-methyl-2-pyridinyl)-3-
propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-28-3

CMF C22 H32 N8


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 792967-31-8 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N5-[(1-methyl-3-piperidinyl)methyl]-N7-(4-methyl-2-pyridinyl)-3-
propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-30-7
CMF C22 H32 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10580306

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 792967-33-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,1-dimethyl-N5-[(1-methyl-3-piperidinyl)methyl]-N7-(4-methyl-2-
pyridinyl)-3-propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 792967-32-9
CMF C23 H34 N8



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 792967-35-2 CAPLUS


10580306

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[2-[(dimethylamino)methyl]-1-piperidiny]-1-methyl-N-(4-methyl-2-
pyridinyl)-3-propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-34-1

CMF C23 H34 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 792967-37-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N7-(4-methyl-2-pyridinyl)-N5-[(1-methyl-2-pyrrolidinyl)methyl]-3-
propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-36-3

CMF C21 H30 N8

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-39-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-1-methyl-N-(4-methyl-2-
pyridinyl)-3-propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-38-5

CMF C22 H30 N8




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-41-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-[2-(dimethylamino)ethyl]-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-40-9

CMF C19 H28 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 792967-43-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,


10580306

N5-[2-(dimethylamino)ethyl]-N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-42-1

CMF C20 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 792967-45-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-[3-(dimethylamino)propyl]-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-44-3

CMF C20 H30 N8


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 792967-47-6 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-[3-(dimethylamino)propyl]-N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-3-
propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-46-5
CMF C21 H32 N8




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-49-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,1-dimethyl-N5-[2-(methylamino)ethyl]-N7-(4-methyl-2-pyridinyl)-3-propyl-
, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-48-7

CMF C19 H28 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




10580306

RN 792967-51-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(3-methyl-1-piperazinyl)-N-(4-methyl-2-pyridinyl)-3-propyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-50-1

CMF C20 H28 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 792967-53-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-N5-(3R)-3-pyrrolidinyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 792967-52-3

CMF C19 H26 N8

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 792967-54-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-N5-[(3S)-3-pyrrolidinylmethyl]-
(CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-56-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)-N-(4-methyl-2-


10580306

pyridinyl)-3-propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-55-6

CMF C22 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 792967-57-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-4-piperidinyl-3-propyl- (CA
INDEX NAME)

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792967-59-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[1-methyl-7-[(4-methyl-2-pyridinyl)amino]-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-58-9

CMF C20 H26 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2

10580306



RN 792967-60-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[4-(methylamino)-1-piperidinyl]-N-(4-methyl-2-pyridinyl)-3-
propyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-61-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3-amino-1-pyrrolidinyl)-1-methyl-N-(4-methyl-2-pyridinyl)-3-propyl-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-62-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-[(4-methoxyphenyl)methyl]-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-
(CA INDEX NAME)

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792967-64-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(2-methoxyethyl)-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-63-6

CMF C18 H25 N7 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 792967-66-9 CAPLUS


10580306

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(6-methyl-3,6-diazabicyclo[3.2.2]non-3-yl)-N-(4-methyl-2-
pyridinyl)-3-propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-65-8

CMF C23 H32 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 792967-68-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N7-(4-methyl-2-pyridinyl)-N5-(4-piperidinylmethyl)-3-propyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-67-0

CMF C21 H30 N8

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 792967-70-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[(2S)-2-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-3-propyl-
, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-69-2

CMF C20 H28 N8

Absolute stereochemistry.




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-72-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[4-[(methylamino)methyl]-1-piperidinyl]-N-(4-methyl-2-
pyridinyl)-3-propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792967-71-6

CMF C22 H32 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2




10580306

RN 792967-73-8 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792967-74-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-3-propyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-75-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(1-piperazinyl)-3-propyl-N-4-pyrimidinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-76-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(4-methyl-1-piperazinyl)-3-propyl-N-4-pyrimidinyl- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-77-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[(3S)-3-methyl-1-piperazinyl]-3-propyl-N-4-pyrimidinyl- (CA
INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-78-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,1-dimethyl-N5-(1-methyl-4-piperidinyl)-3-propyl-N7-4-pyrimidinyl-,
hydrochloride (1:?) (CA INDEX NAME)




●_x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-79-4 CAPLUS

CN	1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(6-methoxy-4-pyrimidinyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (INDEX NAME)	(CA
----	--	-----


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-80-7 CAPLUS


CN 1H-Pyrazolo [4,3-d]pyrimidine-5,7-diamine,
N7-(6-methoxy-4-pyrimidinyl)-N5,1-dimethyl-3-propyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-81-8 CAPLUS


CN	1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(6-methoxy-4-pyrimidinyl)-N5,N5,1-trimethyl-3-propyl-	(CA INDEX NAME)
----	---	-----------------



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


10580306

RN 792967-82-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(1-piperazinyl)-3-propyl-N-2-pyrazinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792967-83-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(1-piperazinyl)-3-propyl-N-2-pyrimidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-84-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(1-piperazinyl)-3-propyl-N-3-pyridazinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-85-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,N5,1-trimethyl-N7-(5-methyl-1,2,4-oxadiazol-3-yl)-3-propyl- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-86-3 CAPLUS

1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-1H-imidazol-2-yl-N5,1-dimethyl-3-propyl- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-87-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-[(3R)-3-methyl-1-piperazinyl]-3-propyl-N-4-pyrimidinyl- (CA
INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-88-5 CAPLUS

CN Ethanol, 2-[[1-(3-methoxypropyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-
1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-89-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,1-bis(2-methoxyethyl)-3-methyl-N7-(4-methyl-2-pyridinyl)- (CA INDEX
NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-90-9 CAPLUS

CN 4-Piperidinol, 1-[3-ethyl-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-91-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-methoxyethyl)-5-[(3S)-3-methoxy-1-pyrrolidinyl]-3-methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-92-1 CAPLUS

CN Ethanol, 2-[[1-(3-methoxypropyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-93-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-methoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-94-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-1-(2-methoxyethyl)-N7-(4-methyl-2-pyridinyl)-N5-[(2S)-2-pyrrolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-95-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(3-methoxypropyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-96-5 CAPLUS

CN 3-Pyrrolidinol, 1-[1-(3-methoxypropyl)-3-methyl-7-[(4-methyl-2-
pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (3R)- (CA INDEX
NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-97-6 CAPLUS

CN β -Alanine, N-[1-(2-methoxyethyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-98-7 CAPLUS

CN 3-Pyrrolidinol, 1-[1-(2-methoxyethyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-99-8 CAPLUS

CN 1-Propanol, 3-[[3-ethyl-1-(2-methoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-00-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(3-methoxypropyl)-3-methyl-N7-(5-methyl-2-pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-01-5 CAPLUS

CN 4-Piperidinol, 1-[1-(2-methoxyethyl)-3-methyl-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-02-6 CAPLUS

CN 2-Piperazinone, 4-[1-(2-methoxyethyl)-3-methyl-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-03-7 CAPLUS

CN Propanamide, 3-[[3-ethyl-1-(2-methoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-N-methyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-04-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-1-(2-methoxyethyl)-N-(5-methyl-2-pyridinyl)-5-(4-morpholinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-05-9 CAPLUS

CN Ethanol, 2-[[3-ethyl-1-(2-methoxyethyl)-7-(2-pyridinylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-06-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N7-(5-fluoro-2-pyridinyl)-N5,1-bis(2-methoxyethyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-07-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-1-(2-methoxyethyl)-N7-(5-propoxy-2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-08-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N7-(5-methyl-2-pyridinyl)-N5-[2-(4-morpholinyl)ethyl]-3-propyl-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-09-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-methyl-5-(4-methyl-1-piperazinyl)-N-(5-methyl-2-pyridinyl)-3-propyl-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-10-6 CAPLUS

CN 1-Propanol, 2-[[7-[(4,6-dimethyl-2-pyridinyl)amino]-1-(3-methoxypropyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-11-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-1-(2-methoxyethyl)-N7-(5-methyl-1H-pyrazol-3-yl)-N5-[2-(1H-pyrazol-1-yl)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-12-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(3-methoxypropyl)-3-methyl-N-(5-methyl-1H-pyrazol-3-yl)-5-(1-piperazinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-13-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(2,5-diazabicyclo[2.2.1]hept-2-yl)-1-(3-methoxypropyl)-3-methyl-N-(5-
methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-14-0 CAPLUS

CN L-Proline, 1-[3-ethyl-1-(2-methoxyethyl)-7-[(5-methyl-1H-pyrazol-3-
yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-15-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-methyl-N5-[2-(methylamino)ethyl]-3-propyl-N7-1H-pyrazol-3-yl- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-16-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(3S)-3-amino-1-pyrrolidinyl]-1-methyl-3-propyl-N-1H-pyrazol-3-yl- (CA
INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-17-3 CAPLUS

CN 3-Piperidinol, 1-[3-ethyl-1-(2-methoxyethyl)-7-(1H-pyrazol-3-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-18-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(3-methoxypropyl)-3-methyl-N-1H-pyrazol-3-yl-5-(1-pyrrolidinyl)- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-19-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(5-ethyl-2-pyridinyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-20-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-cyclohexyl-1-methyl-5-(1-piperazinyl)-3-propyl- (CA INDEX NAME)



RN 792968-21-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4,6-dimethyl-2-pyridinyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-22-0 CAPLUS

CN Cyclohexanol, 4-[[1-methyl-5-(1-piperazinyl)-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 792968-23-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4-methoxycyclohexyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (CA INDEX NAME)

10580306



RN 792968-24-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-6-[[1-methyl-5-(1-piperazinyl)-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-25-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-cyclopentyl-1-methyl-5-(1-piperazinyl)-3-propyl- (CA INDEX NAME)

10580306



RN 792968-26-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,N7,1-trimethyl-N7-(1-methyl-4-piperidinyl)-3-propyl- (CA INDEX NAME)



RN 792968-27-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-methoxyethyl)-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-3-propyl-,
hydrochloride (1:2) (CA INDEX NAME)

10580306




●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-28-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-methoxyethyl)-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)-3-propyl-,
hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-29-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-30-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-31-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-32-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-33-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-34-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-35-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-36-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-37-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-38-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-39-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-40-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-41-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-42-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-43-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-44-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-45-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-46-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-47-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-1-(2-methoxyethyl)-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-48-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-1-(2-methoxyethyl)-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-49-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-1-(2-methoxyethyl)-N7-(4-methyl-2-pyridinyl)-N5-[2-(1H-pyrazol-1-yl)ethyl]-
(CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-50-4 CAPLUS

CN 1-Propanol, 2-[[3-ethyl-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-51-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-methoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3R)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-52-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3R)-1-
methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-53-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,3-dimethyl-N5-[(3R)-1-methyl-3-pyrrolidinyl]-N7-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-54-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-N5-[(3R)-1-
methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-55-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(5-methyl-2-pyridinyl)-N5-[(3R)-1-
methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-56-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-[(3R)-1-methyl-3-pyrrolidinyl]-N7-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-57-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3S)-1-
methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-58-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-N5-[(3S)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-59-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[(tetrahydro-2H-pyran-2-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)

10580306




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-60-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-61-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-methoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-62-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[(tetrahydro-2-
furanyl)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-63-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-(2-pyridinylmethyl)-
(CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-64-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[(tetrahydro-2H-
pyran-2-yl)methyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-65-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[(tetrahydro-3-
furanyl)methyl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-66-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-(2,2,2-
trifluoroethyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-75-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-methoxyethyl)-3-(1-methylethyl)-N-(4-methyl-2-pyridinyl)-5-(1-
piperazinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 792968-74-2

CMF C21 H30 N8 O

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 792968-76-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-methoxyethyl)-3-(1-methylethyl)-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-77-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-1-(2-methoxyethyl)-N-(5-methyl-1H-pyrazol-3-yl)-5-(1-piperazinyl)-

10580306


(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-78-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol,
1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-79-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol,
5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-80-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-N-(4-methyl-2-pyridinyl)-5-(1-
piperazinyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-81-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-
methyl-2-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.

10580306




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-82-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-N5,N5-dimethyl-N7-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-83-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-(4-methyl-2-pyridinyl)-5-(1-
piperazinyl)-, hydrochloride (1:2) (CA INDEX NAME)

10580306




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-84-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-85-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-(ethoxymethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-86-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-
pyrimidinyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-87-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-5-(1-piperazinyl)-N-4-pyrimidinyl-,
hydrochloride (1:2) (CA INDEX NAME)

10580306




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-88-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,3-dimethyl-N5-[(3S)-1-methyl-3-pyrrolidinyl]-N7-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-89-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(5-methyl-2-pyridinyl)-N5-[(3S)-1-
methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-90-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-[(3S)-1-methyl-3-pyrrolidiny]-N7-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-91-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(6-methoxy-3-pyridinyl)-3-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 792968-92-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(5-methoxy-2-pyridinyl)-3-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-93-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-N-(6-methoxy-2-pyridinyl)-3-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-94-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-
pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-95-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-96-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
N-(5,6-dimethyl-3-pyridinyl)-1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-
piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 792968-97-9 CAPLUS

CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-
piperazinyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-methyl- (CA INDEX
NAME)


Absolute stereochemistry.

10580306



RN 792968-98-0 CAPLUS


CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-5-[(2-methoxyethyl)methylamino]-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-methyl- (CA INDEX NAME)



RN 792968-99-1 CAPLUS

CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-5-(ethylmethylamino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-methyl- (CA INDEX NAME)


10580306



RN 792969-01-8 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[3-(methylamino)-1-azetidinyl]-N-(4-methyl-2-
pyridinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 792969-00-7
CMF C20 H28 N8 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2


10580306



RN 792969-03-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[3-(dimethylamino)-1-azetidinyl]-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-
2-pyridinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 792969-02-9
CMF C21 H30 N8 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 792969-04-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-
2-yl]-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-05-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-(2-methoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-
pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-06-3 CAPLUS

CN Ethanol, 2-[[1-(2-ethoxyethyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-
pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-07-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5,3-dimethyl-N7-(6-methyl-2-pyridinyl)-N5-[(3S)-1-
methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-08-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-
2-yl]-N-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-09-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-10-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-ethyl-3-(methoxymethyl)-N5-methyl-N7-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-11-0 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[1-(2-ethoxyethyl)-3-(methoxymethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-12-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(4-methyl-2-pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-13-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-[3-(dimethylamino)-1-azetidinyl]-1-(2-ethoxyethyl)-3-(methoxymethyl)-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-14-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-N5,3-dimethyl-N7-4-pyrimidinyl- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-15-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-ethyl-N5,3-dimethyl-N7-4-pyrimidinyl- (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-16-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-ethyl-N5,3-dimethyl-N7-(2-methyl-4-pyrimidinyl)- (CA
INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-17-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-(2-methoxyethyl)-N5,3-dimethyl-N7-(2-methyl-4-
pyrimidinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-18-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(2-methyl-4-
pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-19-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-
pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-20-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-[4-
(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-21-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-1-[2-
(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-22-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-23-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-ethyl-3-(methoxymethyl)-N5-methyl-N7-4-pyrimidinyl-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-24-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
1-(2-ethoxyethyl)-N5-(2-methoxyethyl)-3-(methoxymethyl)-N5-methyl-N7-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-25-6 CAPLUS

CN Ethanol, 2-[[1-(2-ethoxyethyl)-3-(methoxymethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylanilino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-26-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol, 1-(2-ethoxyethyl)-5-(ethylmethylanilino)-7-(4-pyrimidinylamino)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-27-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-28-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-(methoxymethyl)-N-(4-methyl-2-pyridinyl)-1-(2-propoxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-29-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-methyl-N-(4-methyl-2-
pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-30-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-
2-pyridinyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-31-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-N-(5,6-dimethyl-3-pyridinyl)-1-(2-ethoxyethyl)-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 792969-32-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-33-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(6-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-34-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-35-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(2,5-diazabicyclo[2.2.2]oct-2-yl)-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-
2-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-36-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-3-methyl-N-(6-methyl-2-pyridinyl)-1-[2-(
(2,2,2-trifluoroethoxy)ethyl)- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-37-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-3-methyl-N-(6-methyl-2-pyridinyl)-1-(2-
propoxyethyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-38-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(5-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-39-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-40-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-1-(2-ethoxyethyl)-3-(methoxymethyl)-N-
(4-methyl-2-pyridinyl)- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-41-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 792969-42-7P, N-[5-[(1R,4R)-2,5-Diazabicyclo[2.2.1]hept-2-yl]-1-(2-ethoxyethyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine 792969-43-8P 792969-44-9P 792969-45-0P
, 3-Methyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(6-methylpyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792969-46-1P, N-[3-Ethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]pyridazin-4-ylamine 792969-47-2P,
N-[3-Ethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]pyrimidin-4-ylamine 792969-48-3P, N-[3-Ethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-2-methylpyrimidin-4-ylamine 792969-49-4P,
3-Ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(6-methylpyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine

792969-50-7P, N-[3-Methoxymethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-ylamine 792969-51-8P, N-[3-Methoxymethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine 792969-53-0P, N-[3-Ethoxymethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-ylamine 792969-54-1P, N-[3-Ethoxymethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine 792969-55-2P 792969-56-3P, N-[3-Methyl-5-piperazin-1-yl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-ylamine 792969-57-4P, N-[5-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-3-methoxymethyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine 792969-58-5P 792969-59-6P, 1-[3-Methyl-7-(4-methylpyridin-2-ylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxylic acid 792969-60-9P, 1-[3-Methyl-7-(6-methylpyrimidin-4-ylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxylic acid 792969-61-0P, 1-[3-Ethyl-7-(6-methylpyrimidin-4-ylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxylic acid 792970-85-5P, 3-Methyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(n-propoxy)ethyl]-N-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792970-86-6P, 1-(2-Ethoxyethyl)-3-(methoxymethyl)-5-((3R)-3-methylpiperazin-1-yl)-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792970-87-7P, N-[5-[(1R,4R)-2,5-Diazabicyclo[2.2.1]hept-2-yl]-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine 792970-88-8P, N-[5-[(1S,4S)-2,5-Diazabicyclo[2.2.1]hept-2-yl]-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(PDE5 inhibitor; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in treatment of hypertension)

RN 792969-42-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-43-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3S)-1-methyl-3-pyrrolidinyl]-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-44-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(2-methyl-4-pyrimidinyl)-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-45-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5,3-dimethyl-N5-(1-methyl-4-piperidiny)-N7-(6-methyl-4-pyrimidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-46-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyridazinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 792969-47-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-48-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(2-methyl-4-pyrimidinyl)-1-[2-
(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-49-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(6-methyl-4-pyrimidinyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-50-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-51-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-53-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-54-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-
1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-55-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-56-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-
trifluoroethoxy)ethyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-57-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-3-(methoxymethyl)-N-(4-methyl-2-
pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (CA INDEX NAME)

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-58-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-(methoxymethyl)-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-59-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-60-9 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[3-methyl-7-[(6-methyl-4-pyrimidinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-61-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-ethyl-7-[(6-methyl-4-pyrimidinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (CA INDEX NAME)




10580306

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-85-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-1-(2-propoxyethyl)-N-4-
pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-86-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-87-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-ethyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-88-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine,
5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-ethyl-N-(4-
methyl-2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 792970-50-4P, tert-Butyl 3-[1-(2-ethoxyethyl)-3-methoxymethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate 792970-51-5P, tert-Butyl (1S,4S)-5-[1-(2-ethoxyethyl)-3-methyl-7-(5-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 792970-52-6P, tert-Butyl (1S,4S)-5-[1-(2-ethoxyethyl)-3-methyl-7-[(pyrimidin-4-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 792970-53-7P, tert-Butyl (1S,4S)-5-[1-(2-ethoxyethyl)-3-ethoxymethyl-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 792970-54-8P 792970-84-4P, Ethyl 1-[3-methyl-7-(4-methylpyridin-2-ylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxylate 792970-92-4P 792970-93-5P

10580306


792970-94-6P 792970-95-7P 792970-97-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in treatment of hypertension)

RN 792970-50-4 CAPLUS

CN 3,8-Diazabicyclo[3.2.1]octane-8-carboxylic acid,
3-[1-(2-ethoxyethyl)-3-(methoxymethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-51-5 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid,
5-[1-(2-ethoxyethyl)-3-methyl-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester, (1S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792970-52-6 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid,

10580306

5-[1-(2-ethoxyethyl)-3-methyl-7-(4-pyrimidinylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester, (1S,4S)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-53-7 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[1-(2-ethoxyethyl)-3-(ethoxymethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester, (1S,4S)- (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-54-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)-5-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-84-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, ethyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-92-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(2-methoxyethyl)-3-(1-methylethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-93-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(2-methoxyethyl)-3-(1-methylethyl)-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-94-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-methyl-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-95-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-ethyl-1-(2-methoxyethyl)-7-[(5-methyl-1H-pyrazol-3-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-97-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

10580306



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10580306

L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:771374 CAPLUS

DOCUMENT NUMBER: 139:292259

TITLE: Preparation of pyrazolo[4,3-d]pyrimidines as selective inhibitors of cyclin-dependent kinases, cell proliferation inhibitors, and apoptosis inducers for therapy of diseases

INVENTOR(S): Moravcova, Daniela; Havlicek, Libor; Krystof, Vladimir; Lenobel, Rene

PATENT ASSIGNEE(S): Ustav Experimentalni Botaniky Av Cr (Institute of Experimental Botany Academy of Sciences of the Czech Republic), Czech Rep.

SOURCE: Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1348707	A1	20031001	EP 2002-7163	20020328
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2480409	A1	20031009	CA 2003-2480409	20030327
WO 2003082872	A1	20031009	WO 2003-EP3207	20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003226731	A1	20031013	AU 2003-226731	20030327
AU 2003226731	B2	20080522		
JP 2005527565	T	20050915	JP 2003-580337	20030327
US 20050080097	A1	20050414	US 2004-952087	20040928
PRIORITY APPLN. INFO.:			EP 2002-7163	A 20020328
			WO 2003-EP3207	W 20030327

OTHER SOURCE(S): MARPAT 139:292259


GI



AB The invention relates to 3,5,7-trisubstituted pyrazolo[4,3-d]pyrimidines

represented by the general formula (I) and pharmaceutically acceptable salts thereof [wherein R³ is an optionally substituted alkyl, cycloalkyl, cycloheteroalkyl, cycloalkyl alkyl, aryl or alkylaryl group; R⁵ = halogen, NHNH₂, NHOH, NHCONH₂, guanyl (NH-C(:NH)NH₂) an optionally substituted C1-6 alkyl, alkenyl, alkynyl, C3-15 cycloalkyl, Rf(C3-15 cycloalkyl), heterocycle, heteroalkyl, aryl, heteroaryl, arylalkyl, cycloheteroalkyl, cycloheteroalkyl alkyl, heteroarylalkyl group, the group CORa, CONRbRc, SO₃Rd, or NHC(O)Re [wherein Ra, Rf = optionally substituted C1-6 alkyl, alkenyl, or alkynyl; Rb, Rc, Rd = independently H, optionally substituted C1-6 alkyl, alkenyl, or alkynyl; Re = HO, amino, alkoxy, alkylamino, optionally substituted C1-6 alkyl, alkenyl or alkynyl group, or X-R^{5'} [wherein X = NH, O, S or N(alkyl) and R^{5'} = H, optionally substituted C1-6 alkyl, alkenyl, alkynyl, C3-15 cycloalkyl, Rf(C3-15 cycloalkyl), aryl, heterocycle, hetero C1-6 alkyl, arylalkyl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl alkyl, or heteroarylalkyl, the group CORa, CONRbRc, SO₃Rd, or NHCORe, wherein Ra, Rb, Rc, Rd, Re and Rf have the above meaning]]; R⁷ = halogen, NHNH₂, NHOH, NHCONH₂, guanyl(NH-C(:NH)NH₂) or the group X-R^{7'}, wherein X has the above meaning of R^{7'} is as defined for R^{5'}]. These compds. are useful for treating cancer, or psoriasis, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft vs. host disease and gout, parasitoses such as those caused by fungi or protists, or Alzheimer's disease, or as antineurogenerative drugs, or to suppress immunostimulation. They are also used for treating an hyperproliferative skin disease in a human suffering therefrom by actinic keratosis, Bowen's disease, papilloma, seborrheic keratosis, toxic eczema, atopic dermatitis and ichthyosis. They modulate the activation of adrenergic and/or purinergic receptors which as a consequence result in the activation or inactivation of adenylate cyclase in cancer, asthma, cardiovascular, neurodegenerative and inflammatory diseases. Also disclosed are (1) a method of eliminating or reducing viral spread or growth in tissue culture systems during the production of biopharmaceutical or other products such as proteins and vaccines, for elimination or reduction of viral spread and growth in clin. samples such as blood, and for stopping of growth of tissue culture cells while leaving the cells to carry on with protein and secondary products (antibiotics, secondary plant products, and the like) production, using the compds. I, (2) a method of suppressing immunostimulation (e.g. arthritis or in suppression of transplant rejection) in mammals by administration of I, (3) a method of inducing apoptosis in mammalian cells by administration of I, (4) a method of inhibiting aging and senescence of mammalian cells, the health and youthful appearance of skin and body using I, and (5) a method of maintaining mammalian oocytes at the germinal vesicle stage and their fertilization during mammalian cloning processes by using I. Disclosed is a method of treating viral infections, in particular those caused by DNA viruses including herpesviruses HSV- 1, HSV-2, VZV, EBV, CMV, HHV-6, HHV-7, HHV-8 or vaccinia virus, papilloma viruses, flaviviruses, retroviruses, adenoviruses, cytomegalovirus, and the like.

- IT 607729-12-4D, epoxy activated Sepharose 6B-bound
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (affinity sorbent; preparation of pyrazolo[d]pyrimidines as selective
 inhibitors of cyclin-dependent kinases, cell proliferation inhibitors,
 and apoptosis inducers for therapy of diseases)
- RN 607729-12-4 CAPLUS
- CN Benzoic acid, 5-[[5-[(2-aminopropyl)amino]-3-(1-methylethyl)-1H-
 pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)



IT 607725-51-9P 607725-52-0P 607725-53-1P
 607725-54-2P 607725-55-3P 607725-56-4P
 607725-57-5P 607725-58-6P 607725-59-7P
 607725-60-0P 607725-61-1P 607725-62-2P
 607725-63-3P 607725-64-4P 607725-65-5P
 607725-66-6P 607725-67-7P 607725-68-8P
 607725-69-9P 607725-70-2P 607725-71-3P
 607725-72-4P 607725-73-5P 607725-74-6P
 607725-75-7P 607725-76-8P 607725-77-9P
 607725-78-0P 607725-79-1P 607725-80-4P
 607725-81-5P 607725-82-6P 607725-83-7P
 607725-84-8P 607725-85-9P 607725-86-0P
 607725-87-1P 607725-88-2P 607725-89-3P
 607725-90-6P 607725-91-7P 607725-92-8P
 607725-93-9P 607725-94-0P 607725-95-1P
 607725-96-2P 607725-97-3P 607725-98-4P
 607725-99-5P 607726-00-1P 607726-01-2P
 607726-02-3P 607726-03-4P 607726-04-5P
 607726-05-6P 607726-06-7P 607726-07-8P
 607726-08-9P 607726-09-0P 607726-10-3P
 607726-11-4P 607726-12-5P 607726-13-6P
 607726-14-7P 607726-15-8P 607726-16-9P
 607726-17-0P 607726-18-1P 607726-19-2P
 607726-20-5P 607726-21-6P 607726-22-7P
 607726-23-8P 607726-24-9P 607726-25-0P
 607726-26-1P 607726-27-2P 607726-28-3P
 607726-29-4P 607726-30-7P 607726-31-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[d]pyrimidines as selective inhibitors of cyclin-dependent kinases, cell proliferation inhibitors, and apoptosis inducers for therapy of diseases)


RN 607725-51-9 CAPLUS

CN Ethanol, 2-[[7-[(3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)


10580306



RN 607725-52-0 CAPLUS
CN 1-Propanol, 3-[[7-[(3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)




RN 607725-53-1 CAPLUS
CN Ethanol, 2,2'-[[7-[(3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI) (CA INDEX NAME)




RN 607725-54-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,

10580306

N5-(2-aminocyclohexyl)-N7-(3-chlorophenyl)-3-(1-methylethyl)- (CA INDEX NAME)




RN 607725-55-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(4-aminocyclohexyl)-N7-(3-chlorophenyl)-3-(1-methylethyl)- (CA INDEX NAME)



RN 607725-56-4 CAPLUS
CN 1-Butanol, 2-[[7-[(3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 607725-57-5 CAPLUS


CN 1-Butanol, 2-[[7-[(3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607725-58-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(3-aminopropyl)-N7-(3-chlorophenyl)-3-(1-methylethyl)- (CA INDEX NAME)



RN 607725-59-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(2-aminoethyl)-N7-(3-chlorophenyl)-3-(1-methylethyl)- (CA INDEX NAME)

10580306




RN 607725-60-0 CAPLUS

CN Ethanol, 2-[[[3-(1-methylethyl)-7-(phenylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)




RN 607725-61-1 CAPLUS

CN 1-Propanol, 3-[[[3-(1-methylethyl)-7-(phenylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)




RN 607725-62-2 CAPLUS

CN Ethanol, 2,2'-[[[3-(1-methylethyl)-7-(phenylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI) (CA INDEX NAME)




10580306

RN 607725-63-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(2-aminocyclohexyl)-3-(1-methylethyl)-N7-phenyl- (CA INDEX NAME)




RN 607725-64-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(4-aminocyclohexyl)-3-(1-methylethyl)-N7-phenyl- (CA INDEX NAME)



RN 607725-65-5 CAPLUS
CN 1-Butanol, 2-[[3-(1-methylethyl)-7-(phenylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 607725-66-6 CAPLUS
CN 1-Butanol, 3-methyl-2-[[3-(1-methylethyl)-7-(phenylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 607725-67-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(3-aminopropyl)-3-(1-methylethyl)-N7-phenyl- (CA INDEX NAME)




RN 607725-68-8 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(2-aminoethyl)-3-(1-methylethyl)-N7-phenyl- (CA INDEX NAME)




RN 607725-69-9 CAPLUS
CN Benzoic acid, 2-chloro-4-[[5-[(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)

10580306



RN 607725-70-2 CAPLUS


CN Benzoic acid, 2-chloro-4-[[5-[(3-hydroxypropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 607725-71-3 CAPLUS


CN Benzoic acid, 4-[[5-[bis(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)

10580306



RN 607725-72-4 CAPLUS


CN Benzoic acid, 4-[[5-[(2-aminocyclohexyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)



RN 607725-73-5 CAPLUS

CN Benzoic acid, 4-[[5-[(4-aminocyclohexyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)


10580306



RN 607725-74-6 CAPLUS

CN Benzoic acid, 2-chloro-4-[[5-[[[(1R)-1-(hydroxymethyl)propyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607725-75-7 CAPLUS

CN Benzoic acid, 2-chloro-4-[[5-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)


Absolute stereochemistry.

10580306



RN 607725-76-8 CAPLUS


CN Benzoic acid, 4-[[5-[(3-aminopropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)



RN 607725-77-9 CAPLUS


CN Benzoic acid, 4-[[5-[(2-aminoethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)

10580306



RN 607725-78-0 CAPLUS


CN Benzoic acid, 2-chloro-5-[[5-[(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 607725-79-1 CAPLUS


CN Benzoic acid, 2-chloro-5-[[5-[(3-hydroxypropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)

10580306



RN 607725-80-4 CAPLUS


CN Benzoic acid, 5-[[5-[[bis(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)



RN 607725-81-5 CAPLUS


CN Benzoic acid, 5-[[5-[(2-aminocyclohexyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)

10580306



RN 607725-82-6 CAPLUS

CN Benzoic acid, 5-[[5-[(4-aminocyclohexyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)




RN 607725-83-7 CAPLUS

CN Benzoic acid, 2-chloro-5-[[5-[[[(1R)-1-(hydroxymethyl)propyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 607725-84-8 CAPLUS

CN Benzoic acid, 2-chloro-5-[[5-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)


Absolute stereochemistry.



RN 607725-85-9 CAPLUS


CN Benzoic acid, 5-[[5-[(3-aminopropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)

10580306



RN 607725-86-0 CAPLUS


CN Benzoic acid, 5-[[5-[(2-aminoethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)



RN 607725-87-1 CAPLUS


CN Benzoic acid, 2-hydroxy-5-[[5-[(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)

10580306



RN 607725-88-2 CAPLUS


CN Benzoic acid, 2-hydroxy-5-[[5-[(3-hydroxypropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 607725-89-3 CAPLUS


CN Benzoic acid, 5-[[5-[[bis(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-hydroxy]- (CA INDEX NAME)

10580306



RN 607725-90-6 CAPLUS


CN Benzoic acid, 5-[[5-[(2-aminocyclohexyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-hydroxy- (CA INDEX NAME)



RN 607725-91-7 CAPLUS

CN Benzoic acid, 5-[[5-[(4-aminocyclohexyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-hydroxy- (CA INDEX NAME)


10580306



RN 607725-92-8 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[[5-[[[(1R)-1-(hydroxymethyl)propyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-3-(1-methylethyl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607725-93-9 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[[5-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-3-(1-methylethyl)]- (CA INDEX NAME)


Absolute stereochemistry.

10580306



RN 607725-94-0 CAPLUS


CN Benzoic acid, 5-[[5-[(3-aminopropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-hydroxy- (CA INDEX NAME)



RN 607725-95-1 CAPLUS


CN Benzoic acid, 5-[[5-[(2-aminoethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-hydroxy- (CA INDEX NAME)

10580306



RN 607725-96-2 CAPLUS


CN Ethanol, 2-[[[7-[(4-bromophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)



RN 607725-97-3 CAPLUS


CN 1-Propanol, 3-[[[7-[(4-bromophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)

10580306



RN 607725-98-4 CAPLUS


CN Ethanol, 2,2'-[[7-[(4-bromophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI) (CA INDEX NAME)




RN 607725-99-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(2-aminocyclohexyl)-N7-(4-bromophenyl)-3-(1-methylethyl)- (CA INDEX NAME)

10580306




RN 607726-00-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(4-aminocyclohexyl)-N7-(4-bromophenyl)-3-(1-methylethyl)- (CA INDEX
NAME)



RN 607726-01-2 CAPLUS
CN 1-Butanol, 2-[[7-[(4-bromophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-
d]pyrimidin-5-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 607726-02-3 CAPLUS


CN 1-Butanol, 2-[[7-[(4-bromophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607726-03-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(3-aminopropyl)-N7-(4-bromophenyl)-3-(1-methylethyl)- (CA INDEX NAME)




RN 607726-04-5 CAPLUS

10580306

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(2-aminoethyl)-N7-(4-bromophenyl)-3-(1-methylethyl)- (CA INDEX NAME)




RN 607726-05-6 CAPLUS
CN Ethanol, 2-[[7-[(4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)




RN 607726-06-7 CAPLUS
CN 1-Propanol, 3-[[7-[(4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)

10580306



RN 607726-07-8 CAPLUS


CN Ethanol, 2,2'-[[7-[(4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI) (CA INDEX NAME)



RN 607726-08-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(2-aminocyclohexyl)-N7-(4-chlorophenyl)-3-(1-methylethyl)- (CA INDEX NAME)

10580306



RN 607726-09-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(4-aminocyclohexyl)-N7-(4-chlorophenyl)-3-(1-methylethyl)- (CA INDEX
NAME)




RN 607726-10-3 CAPLUS

CN 1-Butanol, 2-[[7-[(4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-
d]pyrimidin-5-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 607726-11-4 CAPLUS


CN 1-Butanol, 2-[[7-[(4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607726-12-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(3-aminopropyl)-N7-(4-chlorophenyl)-3-(1-methylethyl)- (CA INDEX NAME)




RN 607726-13-6 CAPLUS

10580306

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N5-(2-aminoethyl)-N7-(4-chlorophenyl)-3-(1-methylethyl)- (CA INDEX NAME)




RN 607726-14-7 CAPLUS
CN Ethanol, 2-[[7-[(3-amino-4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)




RN 607726-15-8 CAPLUS
CN 1-Propanol, 3-[[7-[(3-amino-4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)

10580306



RN 607726-16-9 CAPLUS


CN Ethanol, 2,2'-[[7-[(3-amino-4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI) (CA INDEX NAME)




RN 607726-17-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(3-amino-4-chlorophenyl)-N5-(2-aminocyclohexyl)-3-(1-methylethyl)- (CA INDEX NAME)

10580306




RN 607726-18-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(3-amino-4-chlorophenyl)-N5-(4-aminocyclohexyl)-3-(1-methylethyl)- (CA
INDEX NAME)



RN 607726-19-2 CAPLUS
CN 1-Butanol, 2-[[7-[(3-amino-4-chlorophenyl)amino]-3-(1-methylethyl)-1H-
pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10580306



RN 607726-20-5 CAPLUS

CN 1-Butanol, 2-[[7-[(3-amino-4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 607726-21-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(3-amino-4-chlorophenyl)-N5-(3-aminopropyl)-3-(1-methylethyl)- (CA
INDEX NAME)

10580306




RN 607726-22-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(3-amino-4-chlorophenyl)-N5-(2-aminoethyl)-3-(1-methylethyl)- (CA
INDEX NAME)




RN 607726-23-8 CAPLUS
CN Ethanol, 2-[[7-[(4-amino-3-chlorophenyl)amino]-3-(1-methylethyl)-1H-
pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)

10580306



RN 607726-24-9 CAPLUS


CN 1-Propanol, 3-[[7-[(4-amino-3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (CA INDEX NAME)




RN 607726-25-0 CAPLUS

CN Ethanol, 2,2'-[[7-[(4-amino-3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI) (CA INDEX NAME)

10580306




RN 607726-26-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(4-amino-3-chlorophenyl)-N5-(2-aminocyclohexyl)-3-(1-methylethyl)- (CA
INDEX NAME)



RN 607726-27-2 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(4-amino-3-chlorophenyl)-N5-(4-aminocyclohexyl)-3-(1-methylethyl)- (CA
INDEX NAME)


10580306



RN 607726-28-3 CAPLUS

CN 1-Butanol, 2-[[7-[(4-amino-3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 607726-29-4 CAPLUS


CN 1-Butanol, 2-[[7-[(4-amino-3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

10580306




RN 607726-30-7 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(4-amino-3-chlorophenyl)-N5-(3-aminopropyl)-3-(1-methylethyl)- (CA
INDEX NAME)



RN 607726-31-8 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine,
N7-(4-amino-3-chlorophenyl)-N5-(2-aminoethyl)-3-(1-methylethyl)- (CA
INDEX NAME)

10580306



REFERENCE COUNT:

15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10580306

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y